Seroprevalence of anti-SARS-CoV-2 IgG antibodies in G population-based study

Lancet, The

396, 313-319

DOI: 10.1016/s0140-6736(20)31304-0

Citation Report

#	Article	IF	Citations
1	Herd Immunity and Implications for SARS-CoV-2 Control. JAMA - Journal of the American Medical Association, 2020, 324, 2095.	3.8	158
2	Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity. Immunity, 2020, 53, 925-933.e4.	6.6	301
3	Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study. Lancet, The, 2020, 396, 1335-1344.	6.3	257
4	SARS-CoV-2 infections in children and young people. Clinical Immunology, 2020, 220, 108588.	1.4	82
5	The turning point and end of an expanding epidemic cannot be precisely forecast. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 26190-26196.	3.3	117
6	Viruses That Can and Cannot Coexist With Humans and the Future of SARS-CoV-2. Frontiers in Microbiology, 2020, 11, 583252.	1.5	18
7	Visualizing the invisible: The effect of asymptomatic transmission on the outbreak dynamics of COVID-19. Computer Methods in Applied Mechanics and Engineering, 2020, 372, 113410.	3.4	58
8	Serological Tests for SARS-CoV-2 Coronavirus by Commercially Available Point-of-Care and Laboratory Diagnostics in Pre-COVID-19 Samples in Japan. Diseases (Basel, Switzerland), 2020, 8, 36.	1.0	7
9	Presentation, Treatment Response and Short-Term Outcomes in Paediatric Multisystem Inflammatory Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS). Journal of Clinical Medicine, 2020, 9, 3293.	1.0	56
10	Seroprevalence of antiâ€SARSâ€CoVâ€2 antibodies in COVIDâ€19 patients and healthy volunteers up to 6 months post disease onset. European Journal of Immunology, 2020, 50, 2025-2040.	1.6	188
11	Reconstructing the early global dynamics of under-ascertained COVID-19 cases and infections. BMC Medicine, 2020, 18, 332.	2.3	129
12	Antiâ€“SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	110
13	Late incidence of SARS-CoV-2 infection in a highly-endemic remote rural village. A prospective population-based cohort study. Pathogens and Global Health, 2020, 114, 457-462.	1.0	15
14	Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: An up-to-date review. International Journal of Infectious Diseases, 2020, 101, 314-322.	1.5	171
15	Searching for COVID-19 Antibodies in Czech Childrenâ€”A Needle in the Haystack. Frontiers in Pediatrics, 2020, 8, 597736.	0.9	9
16	Tracking SARS-CoV-2 in Sewage: Evidence of Changes in Virus Variant Predominance during COVID-19 Pandemic. Viruses, 2020, 12, 1144.	1.5	123
17	What GI Physicians Need to Know During COVID-19 Pandemic. Digestive Diseases and Sciences, 2020, 66, 2865-2875.	1.1	7
18	A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates. International Journal of Infectious Diseases, 2020, 101, 138-148.	1.5	332

#	Article	IF	Citations
19	Estimation Without Representation: Early Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Studies and the Path Forward. Journal of Infectious Diseases, 2020, 222, 1086-1089.	1.9	34
21	A COVID-19 Hotspot Area: Activities and Epidemiological Findings. Microorganisms, 2020, 8, 1711.	1.6	10
22	Serological follow-up of SARS-CoV-2 asymptomatic subjects. Scientific Reports, 2020, 10, 20048.	1.6	68
23	How to Determine When SARS-CoV-2 Antibody Testing Is or Is Not Useful for Population Screening: A Tutorial. MDM Policy and Practice, 2020, 5, 238146832096306.	0.5	1
24	Mathematical modelling of the dynamics and containment of COVID-19 in Ukraine. Scientific Reports, 2020, 10, 19662.	1.6	68
25	Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020. Journal of Clinical Medicine, 2020, 9, 3569.	1.0	13
26	Evidence of exposure to SARS-CoV-2 in cats and dogs from households in Italy. Nature Communications, 2020, 11, 6231.	5.8	303
27	The Interaction of Natural and Vaccine-Induced Immunity with Social Distancing Predicts the Evolution of the COVID-19 Pandemic. MBio, 2020, 11, .	1.8	23
28	Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands. Nature Communications, 2020, 11, 5744.	5.8	80
29	Seroprevalence of SARS-CoV-2 antibodies in children: a prospective multicentre cohort study. Archives of Disease in Childhood, 2021, 106, 680-686.	1.0	109
30	Cancer Imaging and Patient Care during the COVID-19 Pandemic. Radiology Imaging Cancer, 2020, 2, e200058.	0.7	12
31	Small Area Estimation for Disease Prevalence Mapping. International Statistical Review, 2020, 88, 398-418.	1.1	8
32	Screening and testing for <scp>COVID</scp>â€19 before surgery. ANZ Journal of Surgery, 2020, 90, 1845-1856.	0.3	38
33	SARS-CoV-2 seroprevalence in COVID-19 hotspots. Lancet, The, 2020, 396, 514-515.	6.3	107
34	Head-to-Head Accuracy Comparison of Three Commercial COVID-19 IgM/IgG Serology Rapid Tests. Journal of Clinical Medicine, 2020, 9, 2369.	1.0	30
35	SARS-CoV-2 in Rural Latin America. A Population-based Study in Coastal Ecuador. Clinical Infectious Diseases, 2021, 73, 314-317.	2.9	43
36	The time to do serosurveys for COVID-19 is now. Lancet Respiratory Medicine,the, 2020, 8, 836-838.	5.2	15
37	Clinical and Laboratory Diagnosis of SARS-CoV-2, the Virus Causing COVID-19. ACS Infectious Diseases, 2020, 6, 2319-2336.	1.8	57

#	Article	IF	Citations
38	Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nature Communications, 2020, 11, 3774.	5.8	78
39	Resetting the Initial Conditions for Calculating Epidemic Spread: COVID-19 Outbreak in Italy. IEEE Access, 2020, 8, 148021-148030.	2.6	3
40	Seroprevalence and immunity of SARS-CoV-2 infection in children and adolescents in schools in Switzerland: design for a longitudinal, school-based prospective cohort study. International Journal of Public Health, 2020, 65, 1549-1557.	1.0	34
41	Prevalence of Current and Past SARS-CoV-2 Infections among Police Employees in Poland, Juneâ€“July 2020. Journal of Clinical Medicine, 2020, 9, 3245.	1.0	11
42	Alternative graphical displays for the monitoring of epidemic outbreaks, with application to COVID-19 mortality. BMC Medical Research Methodology, 2020, 20, 248.	1.4	4
43	Rapid Antibody-Based COVID-19 Mass Surveillance: Relevance, Challenges, and Prospects in a Pandemic and Post-Pandemic World. Journal of Clinical Medicine, 2020, 9, 3372.	1.0	54
44	Lâ€™Ã©pidÃ©mie de COVID-19Â: une autre histoire pourrait Ãªtre racontÃ©e. La Presse MÃ©dicale Formation, 2020, 1, 447-450.	0.1	0
45	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Fatality Rate Among Elderly Danes: A Cross-sectional Study on Retired Blood Donors. Clinical Infectious Diseases, 2021, 73, e2962-e2969.	2.9	20
46	SARS-CoV-2 Infections in the World: An Estimation of the Infected Population and a Measure of How Higher Detection Rates Save Lives. Frontiers in Public Health, 2020, 8, 489.	1.3	11
47	Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors. Journal of Clinical Medicine, 2020, 9, 2780.	1.0	71
48	SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic. ESMO Open, 2020, 5, e000889.	2.0	39
49	SARS-CoV-2 in children: spectrum of disease, transmission and immunopathological underpinnings. Pathology, 2020, 52, 801-808.	0.3	71
50	Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infectious Diseases, The, 2020, 20, 1390-1400.	4.6	336
51	Transmission dynamics reveal the impracticality of COVID-19 herd immunity strategies. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 25897-25903.	3.3	77
52	Meta-analysis of diagnostic performance of serology tests for COVID-19: impact of assay design and post-symptom-onset intervals. Emerging Microbes and Infections, 2020, 9, 2200-2211.	3.0	54
53	Seroprevalence of SARS-CoV-2â€“specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data. Cancer Treatment Reviews, 2020, 90, 102102.	3.4	27
54	Culture-Competent SARS-CoV-2 in Nasopharynx of Symptomatic Neonates, Children, and Adolescents. Emerging Infectious Diseases, 2020, 26, 2494-2497.	2.0	129
55	Coronavirus disease 2019 population-based prevalence, risk factors, hospitalization, and fatality rates in southern Brazil. International Journal of Infectious Diseases, 2020, 100, 402-410.	1.5	15

#	Article	IF	Citations
56	Are Seroprevalence Estimates for Severe Acute Respiratory Syndrome Coronavirus 2 Biased?. Journal of Infectious Diseases, 2020, 222, 1772-1775.	1.9	81
57	Persistent symptoms 3â€…months after a SARS-CoV-2 infection: the post-COVID-19 syndrome?. ERJ Open Research, 2020, 6, 00542-2020.	1.1	554
58	<scp>SARSâ€CoV</scp>â€2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities. IUBMB Life, 2020, 72, 2313-2330.	1.5	10
59	Reconsidering Assumptions of Adolescent and Young Adult Severe Acute Respiratory Syndrome Coronavirus 2 Transmission Dynamics. Clinical Infectious Diseases, 2021, 73, S146-S163.	2.9	31
60	Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma. PLoS ONE, 2020, 15, e0238089.	1.1	71
61	COVID â€19 and children with diabetes: emerging knowledge. Practical Diabetes, 2020, 37, 147.	0.1	2
62	Bayesian Analysis of Tests with Unknown Specificity and Sensitivity. Journal of the Royal Statistical Society Series C: Applied Statistics, 2020, 69, 1269-1283.	0.5	76
63	Global, regional, and national estimates of target population sizes for covid-19 vaccination: descriptive study. BMJ, The, 2020, 371, m4704.	3.0	140
64	Post-Mortem Diagnosis and Autopsy Findings in SARS-CoV-2 Infection: Forensic Case Series. Diagnostics, 2020, 10, 1070.	1.3	16
65	â€˜Dark matterâ€™, second waves and epidemiological modelling. BMJ Global Health, 2020, 5, e003978.	2.0	11
66	Humoral Responses and Serological Assays in SARS-CoV-2 Infections. Frontiers in Immunology, 2020, 11, 610688.	2.2	190
67	Evaluating SARS-CoV-2 Seroconversion Following Relieve of Confinement Measures. Frontiers in Medicine, 2020, 7, 603996.	1.2	9
68	Generic and Respiratory-Specific Quality of Life in Non-Hospitalized Patients with COVID-19. Journal of Clinical Medicine, 2020, 9, 3993.	1.0	52
69	Country performance against COVID-19: rankings for 35 countries. BMJ Global Health, 2020, 5, e003047.	2.0	18
70	Differences of SARS-CoV-2 serological test performance between hospitalized and outpatient COVID-19 cases. Clinica Chimica Acta, 2020, 511, 352-359.	0.5	15
71	Estimating the cumulative rate of SARS-CoV-2 infection. Economics Letters, 2020, 197, 109652.	0.9	2
72	Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. European Journal of Epidemiology, 2020, 35, 1123-1138.	2.5	603
73	Lockdown measures and relative changes in the age-specific incidence of SARS-CoV-2 in Spain. Epidemiology and Infection, 2020, 148, e268.	1.0	5

#	Article	IF	Citations
74	Pervasive RNA Secondary Structure in the Genomes of SARS-CoV-2 and Other Coronaviruses. MBio, 2020, 11, .	1.8	36
75	COVID-19 in children: current evidence and key questions. Current Opinion in Infectious Diseases, 2020, 33, 540-547.	1.3	49
76	Estimating the Percentage of a Population Infected with SARS-CoV-2 Using the Number of Reported Deaths: A Policy Planning Tool. Pathogens, 2020, 9, 838.	1.2	6
77	Corona Immunitas: study protocol of a nationwide program of SARS-CoV-2 seroprevalence and seroepidemiologic studies in Switzerland. International Journal of Public Health, 2020, 65, 1529-1548.	1.0	77
78	Anti-SARS-CoV-2 antibody detection in healthcare workers of two tertiary hospitals in Athens, Greece. Clinical Immunology, 2020, 221, 108619.	1.4	12
79	Seroprevalence of COVID-19 in Taiwan revealed by testing anti-SARS-CoV-2 serological antibodies on 14,765 hospital patients. The Lancet Regional Health - Western Pacific, 2020, 3, 100041.	1.3	21
80	Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests. Journal of Clinical Virology, 2020, 129, 104544.	1.6	73
81	Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet, The, 2020, 396, 535-544.	6.3	1,465
82	Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies. Journal of Virology, 2021, 95, .	1.5	200
83	Immunity passports to travel during the COVID-19 pandemic: controversies and public health risks. Journal of Public Health, 2021, 43, e135-e136.	1.0	19
84	Shielding against SARSâ€CoVâ€2 infection is not justified in children with severe asthma. Pediatric Allergy and Immunology, 2021, 32, 198-198.	1.1	7
85	Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland. Lancet Infectious Diseases, The, 2021, 21, e69-e70.	4.6	135
87	Screening for SARS-CoV-2 antibodies among healthcare workers in a university hospital in southern France. Journal of Infection, 2021, 82, e29-e32.	1.7	14
88	Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults. JAMA Pediatrics, 2021, 175, 143.	3.3	707
89	Independent Side-by-Side Validation and Comparison of 4 Serological Platforms for SARS-CoV-2 Antibody Testing. Journal of Infectious Diseases, 2021, 223, 796-801.	1.9	51
90	High seroprevalence but shortâ€lived immune response to SARSâ€CoVâ€2 infection in Paris. European Journal of Immunology, 2021, 51, 180-190.	1.6	54
91	Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study. Clinical Microbiology and Infection, 2021, 27, 633.e1-633.e7.	2.8	49
92	Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave. Journal of Epidemiology and Community Health, 2021, 75, 489-495.	2.0	88

#	Article	IF	Citations
93	Populationâ€based prevalence surveys during the Covidâ€19 pandemic: A systematic review. Reviews in Medical Virology, 2021, 31, e2200.	3.9	33
94	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, The, 2021, 397, 99-111.	6.3	3,887
95	Low-dose and oral exposure to SARS-CoV-2 may help us understand and prevent severe COVID-19. International Journal of Infectious Diseases, 2021, 103, 37-41.	1.5	8
96	Seroprevalence of antiâ€“SARS-CoV-2 IgG antibodies in Kenyan blood donors. Science, 2021, 371, 79-82.	6.0	247
97	Leveraging epidemiological principles to evaluate Swedenâ€™s COVID-19 response. Annals of Epidemiology, 2021, 54, 21-26.	0.9	42
98	Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2. Science, 2021, 371, .	6.0	341
99	Prevalence of Immunoglobulin G (IgG) Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Evaluation of a Rapid MEDsan IgG Test in Children Seeking Medical Care. Clinical Infectious Diseases, 2021, 72, e192-e195.	2.9	12
100	Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis. Journal of Hospital Infection, 2021, 108, 120-134.	1.4	265
101	A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children. Med, 2021, 2, 149-163.e4.	2.2	85
102	Estimation of Covid-19 prevalence from serology tests: A partial identification approach. Journal of Econometrics, 2021, 220, 193-213.	3.5	13
103	Age-specific mortality and immunity patterns of SARS-CoV-2. Nature, 2021, 590, 140-145.	13.7	883
104	Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science, 2021, 371, 288-292.	6.0	412
105	Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic. Public Health, 2021, 190, 132-134.	1.4	18
106	On the Effect of Age on the Transmission of SARS-CoV-2 in Households, Schools, and the Community. Journal of Infectious Diseases, 2021, 223, 362-369.	1.9	257
107	Is there a role for childhood vaccination against COVIDâ€19?. Pediatric Allergy and Immunology, 2021, 32, 9-16.	1.1	38
108	SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clinical Microbiology and Infection, 2021, 27, 331-340.	2.8	296
109	Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study. American Journal of Medicine, 2021, 134, 526-534.e11.	0.6	28
110	SARSâ€CoVâ€2 and COVIDâ€19 for the ophthalmologist. Clinical and Experimental Ophthalmology, 2021, 49, 70-80.	1.3	8

#	Article	IF	Citations
111	Community seroprevalence of COVID-19 in probable and possible cases at primary health care centres in Spain. Family Practice, 2021, 38, 153-158.	0.8	16
112	Seroprevalence of anti-SARS-CoV-2 antibodies in residents of Karachiâ€"challenges in acquiring herd immunity for COVID 19. Journal of Public Health, 2021, 43, 3-8.	1.0	23
115	Seroepidemiological Survey of the Antibody for Severe Acute Respiratory Syndrome Coronavirus 2 with Neutralizing Activity at Hospitals: A Cross-sectional Study in Hyogo Prefecture, Japan. JMA Journal, 2021, 4, 41-49.	0.6	10
116	Estimating the case fatality ratio for COVID-19 using a time-shifted distribution analysis. Epidemiology and Infection, 2021, 149, e197.	1.0	9
117	Modelling SARS-CoV-2 unreported cases in Italy: Analysis of serological survey and vaccination scenarios. Infectious Disease Modelling, 2021, 6, 909-923.	1.2	3
118	Reopening Schools and the Dynamics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections in Israel: A Nationwide Study. Clinical Infectious Diseases, 2021, 73, 2265-2275.	2.9	21
119	COVID-19 epidemiology in Canada from January to December 2020: the pre-vaccine era. Facets, 2021, 6, 760-822.	1.1	11
120	Seroprevalence of Anti-Sars-Cov-2 Antibodies in Colombia, 2020: A Population-Based Study. SSRN Electronic Journal, 0, , .	0.4	6
122	Pandemic Viruses at Hajj: Influenza and COVID-19. , 2021, , 1-19.		0
124	Pandemic Viruses at Hajj: Influenza and COVID-19. , 2021, , 1249-1266.		0
125	<scp>COVID</scp>â€19 by numbers â€•infections, cases and deaths. Environmental Microbiology, 2021, 23, 1322-1333.	1.8	6
126	National Survey: Knowledge, Attitude and Practice Towards COVID-19 among Iraqi Pharmacy Students. Archives of Pharmacy Practice, 2021, 12, 54-59.	0.2	4
127	Viral co-infections among SARS-CoV-2-infected children and infected adult household contacts. European Journal of Pediatrics, 2021, 180, 1991-1995.	1.3	17
128	Seroprevalence of anti-SARS-CoV-2 of IgG antibody by ELISA: Community-based, cross-sectional study from urban area of Malegaon, Maharashtra. Journal of Family Medicine and Primary Care, 2021, 10, 1453.	0.3	4
129	SeguranÃ§a e educaÃ§Ã£o durante a COVID-19: prevalÃªncia, fatores associados e planos de reabertura da Faculdade de Enfermagem. Escola Anna Nery, 2021, 25, .	0.2	0
130	Towards Bayesian Evaluation of Seroprevalence Studies. Medical Sciences Forum, 2021, 4, .	0.5	0
131	SARS-CoV-2 Seroprevalence in Lithuania: Results of National Population Survey. Acta Medica Lituanica, 2021, 28, 2.	0.2	16
133	COVID-19 SEROSURVEILLANCE POSITIVITY IN GENERAL POPULATION: COMPARISON AT DIFFERENT TIMES. National Journal of Community Medicine, 2021, , 1.	0.1	1

#	Article	IF	Citations
134	COVID-19 y enfermedad pulmonar pediÃ¡trica: Experiencia en un centro de atenciÃ³n terciaria en SudÃ¡frica. Karger Kompass NeumologÃa, 2021, 3, 39-45.	0.0	1
135	Prevalence of virological and serological markers of SARS-CoV-2 infection in the population of RibeirÃ£o Preto, Southeast Brazil: an epidemiological survey. Revista Da Sociedade Brasileira De Medicina Tropical, 2021, 54, e02102021.	0.4	2
136	Jobs, Housing, and Mask Wearing: Cross-Sectional Study of Risk Factors for COVID-19. JMIR Public Health and Surveillance, 2021, 7, e24320.	1.2	20
137	Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: a cross-sectional study. BMJ Open, 2021, 11, e044101.	0.8	21
138	The seroprevalence of severe acute respiratory syndrome coronavirus 2 in Delhi, India: a repeated population-based seroepidemiological study. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2022, 116, 242-251.	0.7	25
139	Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. Journal of Global Health, 2021, 11, 05005.	1.2	71
140	Evaluating the longitudinal effectiveness of preventive measures against COVID-19 and seroprevalence of IgG antibodies to SARS-CoV-2 in cancer outpatients and healthcare workers. Wiener Klinische Wochenschrift, 2021, 133, 359-363.	1.0	9
141	Structural Mapping of Mutations in Spike, RdRp and Orf3a Genes of SARS-CoV-2 in Influenza Like Illness (ILI) Patients. Viruses, 2021, 13, 136.	1.5	4
143	SARS-CoV-2 Seroprevalence and Associated Factors in Manaus, Brazil: Baseline Results from the DETECTCoV-19 Cohort Study. SSRN Electronic Journal, 0, , .	0.4	3
144	HIV and SARS-CoV-2 co-infection: cross-sectional findings from a German â€˜hotspotâ€™. Infection, 2021, 49, 313-320.	2.3	8
146	An indirect method to monitor the fraction of people ever infected with COVID-19: An application to the United States. PLoS ONE, 2021, 16, e0245845.	1.1	11
147	Population-based seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city. Journal of Family Medicine and Primary Care, 2021, 10, 2363.	0.3	5
148	Estimating the cumulative incidence of SARS-CoV-2 with imperfect serological tests: Exploiting cutoff-free approaches. PLoS Computational Biology, 2021, 17, e1008728.	1.5	16
152	Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19). Acta Medica Portuguesa, 2021, 34, 87-94.	0.2	29
153	High Rates of SARS-CoV-2 Family Transmission in Children of Healthcare Workers During the First Pandemic Wave in Madrid, Spain. Pediatric Infectious Disease Journal, 2021, 40, e185-e188.	1.1	8
154	The natural history of symptomatic COVID-19 during the first wave in Catalonia. Nature Communications, 2021, 12, 777.	5.8	53
155	Prevalence of SARS-CoV-2 Infection in Children by Antibody Detection in Saliva: Protocol for a Prospective Longitudinal Study (Coro-Buddy). JMIR Research Protocols, 2021, 10, e27739.	0.5	1
156	Higher SARS-CoV-2 seroprevalence in workers with lower socioeconomic status in Cape Town, South Africa. PLoS ONE, 2021, 16, e0247852.	1.1	45

#	Article	IF	Citations
157	Who should be prioritized for COVID-19 vaccination in China? A descriptive study. BMC Medicine, 2021, 19, 45.	2.3	56
158	Prevalence of SARS-CoV-2â€“Specific Antibodies, Japan, June 2020. Emerging Infectious Diseases, 2021, 27, 628-631.	2.0	28
159	SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic. Nature Communications, 2021, 12, 905.	5.8	168
161	Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications. Frontiers in Immunology, 2021, 12, 627285.	2.2	37
162	The role of children in the spread of COVID-19: Using household data from Bnei Brak, Israel, to estimate the relative susceptibility and infectivity of children. PLoS Computational Biology, 2021, 17, e1008559.	1.5	153
163	The origin and early spread of SARS-CoV-2 in Europe. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	83
164	Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, Augustâ€“October 2020. Emerging Infectious Diseases, 2021, 27, 666-669.	2.0	9
166	Primary Care Relevant Risk Factors for Adverse Outcomes in Patients With COVID-19 Infection: A Systematic Review. Journal of the American Board of Family Medicine, 2021, 34, S113-S126.	0.8	17
168	Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020. Emerging Infectious Diseases, 2021, 27, 636-638.	2.0	66
169	Impact of physical distancing measures against COVID-19 on contacts and mixing patterns: repeated cross-sectional surveys, the Netherlands, 2016â€“17, April 2020 and June 2020. Eurosurveillance, 2021, 26, .	3.9	59
170	COVID-19 in healthcare workers (literature review and own data). Meditsina Truda I Promyshlennaia Ekologiia, 2021, 61, 18-26.	0.1	7
171	Changes in Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Over Time in 10 Sites in the United States, Marchâ€“August, 2020. Clinical Infectious Diseases, 2021, 73, 1831-1839.	2.9	15
172	Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, Augustâ€“October 2020. Emerging Infectious Diseases, 2021, 27, 666-669.	2.0	19
173	Potential Efficacy of Nutrient Supplements for Treatment or Prevention of COVID-19. Journal of Dietary Supplements, 2022, 19, 336-365.	1.4	13
174	SARS-CoV-2 antibody testing for estimating COVID-19 prevalence in the population. Cell Reports Medicine, 2021, 2, 100191.	3.3	32
175	Development and Validation of the COVID-NoLab and COVID-SimpleLab Risk Scores for Prognosis in 6 US Health Systems. Journal of the American Board of Family Medicine, 2021, 34, S127-S135.	0.8	15
176	Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland. Lancet Regional Health - Europe, The, 2021, 1, 100013.	3.0	66
177	Estimated seroprevalence of SARS-CoV-2 antibodies among adults in Orange County, California. Scientific Reports, 2021, 11, 3081.	1.6	39

#	Article	IF	Citations
181	Prevalence of SARS-CoV-2-Antibodies in Danish Children and Adults. Pediatric Infectious Disease Journal, 2021, 40, e157-e159.	1.1	9
182	Prevalence of SARS-CoV-2 in Household Members and Other Close Contacts of COVID-19 Cases: A Serologic Study in Canton of Vaud, Switzerland. Open Forum Infectious Diseases, 2021, 8, ofab149.	0.4	18
183	Advanced microscopy technologies enable rapid response to<scp>SARSâ€CoV</scp>â€2 pandemic. Cellular Microbiology, 2021, 23, e13319.	1.1	7
184	Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Random Sample of Inhabitants of the Katowice Region, Poland. International Journal of Environmental Research and Public Health, 2021, 18, 3188.	1.2	21
185	Incidence, household transmission, and neutralizing antibody seroprevalence of Coronavirus Disease 2019 in Egypt: Results of a community-based cohort. PLoS Pathogens, 2021, 17, e1009413.	2.1	21
187	SARS-CoV-2 antibody seroprevalence in India, Augustâ€"September, 2020: findings from the second nationwide household serosurvey. The Lancet Global Health, 2021, 9, e257-e266.	2.9	155
188	Are we using the right method to estimate the number of COVID-19 cases?. Pathogens and Global Health, 2021, 115, 279-280.	1.0	0
189	Risk at mass-gathering events and the usefulness of complementary events during COVID-19 pandemic. Journal of Infection, 2021, 82, e20-e21.	1.7	11
190	The seroprevalence of SARS-CoV-2 IgG antibodies among asymptomatic blood donors in Saudi Arabia. Saudi Journal of Biological Sciences, 2021, 28, 1697-1701.	1.8	26
191	SARS-Cov-2 Seroprevalence in a French Kidney Transplant Center Located Within a â€œHigh Riskâ€•Zone. Transplantation, 2021, Publish Ahead of Print, 2165-2169.	0.5	0
192	Interactions between seasonal human coronaviruses and implications for the SARS-CoV-2 pandemic: A retrospective study in Stockholm, Sweden, 2009-2020. Journal of Clinical Virology, 2021, 136, 104754.	1.6	25
193	Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China. The Lancet Regional Health - Western Pacific, 2021, 8, 100094.	1.3	41
197	Seroepidemiology of SARS-CoV-2, Yamagata, Japan, June 2020. Western Pacific Surveillance and Response Journal: WPSAR, 2021, 12, 69-71.	0.3	2
198	Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys. ELife, 2021, 10, .	2.8	59
199	SARS-CoV-2 Antibody Seroprevalence Among Maintenance Dialysis Patients in the United States. Kidney Medicine, 2021, 3, 216-222.e1.	1.0	11
200	COVID-19 in Children: Respiratory Involvement and Some Differences With the Adults. Frontiers in Pediatrics, 2021, 9, 622240.	0.9	15
201	Prevalence and Risk Factors of Infection in the Representative COVID-19 Cohort Munich. International Journal of Environmental Research and Public Health, 2021, 18, 3572.	1.2	47
202	Seroprevalence of SARS-CoV-2 IgG antibodies among health care workers prior to vaccine administration in Europe, the USA and East Asia: A systematic review and meta-analysis. EClinicalMedicine, 2021, 33, 100770.	3.2	56

#	Article	IF	Citations
203	Clustering and longitudinal change in SARS-CoV-2 seroprevalence in school children in the canton of Zurich, Switzerland: prospective cohort study of 55 schools. BMJ, The, 2021, 372, n616.	3.0	68
204	Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroconversion and occupational exposure of employees at a Swiss university hospital: A large longitudinal cohort study. Infection Control and Hospital Epidemiology, 2022, 43, 326-333.	1.0	16
208	Disparities in Seroprevalence of SARS-CoV-2 Immunoglobulin Antibodies in a Large Midwestern Health Care System. Public Health Reports, 2021, 136, 361-367.	1.3	15
209	Open schools! Weighing the effects of viruses and lockdowns on children. Trends in Neuroscience and Education, 2021, 22, 100151.	1.5	22
211	Coronavirus disease 2019 and pediatric anesthesia. Current Opinion in Anaesthesiology, 2021, 34, 292-298.	0.9	1
212	Spread of SARS-CoV-2 among primary school pupils: State-of-the-art. Pediatrie Pro Praxi, 2021, 22, 87-89.	0.1	0
213	Seroprevalence of Antibodies against SARS-CoV-2 in Children with Juvenile Idiopathic Arthritis a Case-Control Study. Journal of Clinical Medicine, 2021, 10, 1771.	1.0	3
214	Seroprevalence of anti-SARS-CoV-2 IgG among adolescents at military fitness-for-duty evaluation. BMJ Military Health, 2021, , bmjmilitary-2021-001828.	0.4	0
215	Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review. PLoS ONE, 2021, 16, e0248946.	1.1	71
216	Seroprevalence of SARS-CoV-2 antibody among healthcare workers in a university hospital in Mallorca, Spain, during the first wave of the COVID-19 pandemic. International Journal of Infectious Diseases, 2021, 105, 482-486.	1.5	9
217	Maximizing and evaluating the impact of test-trace-isolate programs: A modeling study. PLoS Medicine, 2021, 18, e1003585.	3.9	43
218	A high-throughput microfluidic nanoimmunoassay for detecting antiâ€“SARS-CoV-2 antibodies in serum or ultralow-volume blood samples. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	44
219	SARS-CoV-2 Antibody Seroprevalence in Wuhan, China, from 23 April to 24 May 2020. MSphere, 2021, 6, .	1.3	0
220	Asymptomatic Sars- Cov-2 Infection among Healthcare Workers in a Non-Covid-19 Teaching University Hospital. Journal of Public Health Research, 2021, 10, jphr.2021.2102.	0.5	7
221	Reconciling estimates of global spread and infection fatality rates of COVIDâ€19: An overview of systematic evaluations. European Journal of Clinical Investigation, 2021, 51, e13554.	1.7	83
222	INVESTIGATION OF SEROPREVALENCE OF IgG ANTIBODIES AMONG HEALTH CARE WORKERS IN VIRAL RESEARCH AND DIAGNOSTIC LABORATORY, AMRITSAR. , 2021, , 63-65.		0
223	SARS-CoV-2 seroprevalence study in Lambayeque, Peru. Juneâ€“July 2020. PeerJ, 2021, 9, e11210.	0.9	30
224	Nationwide seroprevalence of antibodies to SARS-CoV-2 in asymptomatic population in South Korea: a cross-sectional study. BMJ Open, 2021, 11, e049837.	0.8	14

#	Article	IF	Citations
225	Mass SARS-CoV-2 molecular and serological screening of medical staff and patients in Hangzhou, China: no evidence of RNA detection, low seroprevalence, and limited exposure risk in the hospital setting. Annals of Translational Medicine, 2021, 9, 552-552.	0.7	0
226	Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic. Expert Review of Clinical Immunology, 2021, 17, 561-571.	1.3	10
227	Seroprevalence of SARS-CoV-2 Antibodies in Adults and Healthcare Workers in Southern Italy. International Journal of Environmental Research and Public Health, 2021, 18, 4761.	1.2	17
229	Head-to-Head Evaluation of Five Automated SARS-CoV-2 Serology Immunoassays in Various Prevalence Settings. Journal of Clinical Medicine, 2021, 10, 1605.	1.0	5
233	SARS-CoV-2 population-based seroprevalence studies in Europe: a scoping review. BMJ Open, 2021, 11, e045425.	0.8	43
234	Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection. Cell Reports Medicine, 2021, 2, 100228.	3.3	66
238	Evaluating alternative hypotheses to explain the downward trend in the indices of the COVID-19 pandemic death rate. PeerJ, 2021, 9, e11150.	0.9	4
239	Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing. Heliyon, 2021, 7, e06836.	1.4	11
240	Relationship of Test Positivity Rates with COVID-19 Epidemic Dynamics. International Journal of Environmental Research and Public Health, 2021, 18, 4655.	1.2	27
241	The importance of anosmia, ageusia and age in community presentation of symptomatic and asymptomatic SARS-CoV-2 infection in Louisiana, USA; a cross-sectional prevalence study. Clinical Microbiology and Infection, 2021, 27, 633.e9-633.e16.	2.8	8
242	Intra-Household and Close-Contact SARS-CoV-2 Transmission Among Children â€“ a Systematic Review. Frontiers in Pediatrics, 2021, 9, 613292.	0.9	33
243	Seroprevalence of COVID-19 infection in the Emirate of Abu Dhabi, United Arab Emirates: a population-based cross-sectional study. International Journal of Epidemiology, 2021, 50, 1077-1090.	0.9	20
244	SARS-CoV-2 Ig G among Healthcare Workers and the General Population. Pathogens, 2021, 10, 465.	1.2	2
246	Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania,) Tj ETQq1 1 0.784314 rgBT /Overlo	0.9	12
247	SARS-CoV-2 IgG Antibodies Seroprevalence and Sera Neutralizing Activity in MEXICO: A National Cross-Sectional Study during 2020. Microorganisms, 2021, 9, 850.	1.6	19
248	SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020. Eurosurveillance, 2021, 26, .	3.9	69
250	Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. JAMA Internal Medicine, 2021, 181, 450.	2.6	273
251	Discrimination of SARS-CoV-2 infected patient samples by detection dogs: A proof of concept study. PLoS ONE, 2021, 16, e0250158.	1.1	44

#	Article	IF	Citations
252	Laboratory correlates of SARS-CoV-2 seropositivity in a nationwide sample of patients on dialysis in the U.S.. PLoS ONE, 2021, 16, e0249466.	1.1	1
254	Population-Based Estimates of SARS-CoV-2 Seroprevalence in Houston, TX as of September 2020. Journal of Infectious Diseases, 2021, , .	1.9	6
255	Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel. European Journal of Epidemiology, 2021, 36, 727-734.	2.5	33
256	Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany. Nature Communications, 2021, 12, 2117.	5.8	70
257	Pernio (Chilblains), SARS-CoV-2, and COVID Toes Unified Through Cutaneous and Systemic Mechanisms. Mayo Clinic Proceedings, 2021, 96, 989-1005.	1.4	23
258	Current and innovative methods for the diagnosis of COVIDâ€'19 infection (Review). International Journal of Molecular Medicine, 2021, 47, .	1.8	110
259	Prevalence of SARS-CoV-2 in urban and rural Ethiopia:ÂRandomized household serosurveys reveal level of spread during the first wave of the pandemic. EClinicalMedicine, 2021, 35, 100880.	3.2	28
260	Waning antibodies to SARS-CoV-2 â€“ Don't panic. Lancet Regional Health - Europe, The, 2021, 4, 100115.	3.0	8
263	Seroepidemiological study of SARS-CoV-2 infection in East Java, Indonesia. PLoS ONE, 2021, 16, e0251234.	1.1	21
264	Low incidence of COVID-19 severe complications in a large cohort of children with sickle cell disease: a protective role for basal interferon-1 activation?. Haematologica, 2021, 106, 2746-2748.	1.7	6
265	A retrospective cohort study of 12,306 pediatric COVID-19 patients in the United States. Scientific Reports, 2021, 11, 10231.	1.6	83
266	Risk of Reinfection After Seroconversion to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Population-based Propensity-score Matched Cohort Study. Clinical Infectious Diseases, 2022, 74, 622-629.	2.9	61
267	On the increasing incidence of SARS-CoV- 2 in older adolescents and younger adults during the epidemic in Mexico. Salud Publica De Mexico, 2021, 63, 422-428.	0.1	6
268	Seropositivity in blood donors and pregnant women during the first year of SARSâ€CoVâ€2 transmission in Stockholm, Sweden. Journal of Internal Medicine, 2021, 290, 666-676.	2.7	34
269	Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak. Lancet Infectious Diseases, The, 2021, 21, 600-601.	4.6	59
270	bootCombâ€"an R package to derive confidence intervals for combinations of independent parameter estimates. International Journal of Epidemiology, 2021, 50, 1071-1076.	0.9	15
272	Prevalence of COVID â€19 and seroprevalence to SARSâ€CoV â€2 in a rheumatologic patient population from a tertiary referral clinic in Israel. Internal Medicine Journal, 2021, 51, 682-690.	0.5	2
273	Seroprevalence of SARS-CoV-2 antibodies in Seattle, Washington: October 2019â€"April 2020. PLoS ONE, 2021, 16, e0252235.	1.1	2

#	Article	IF	Citations
275	Incorporating false negative tests in epidemiological models for SARS-CoV-2 transmission and reconciling with seroprevalence estimates. Scientific Reports, 2021, 11, 9748.	1.6	16
276	Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance. Nature Communications, 2021, 12, 3025.	5.8	66
278	SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar. Open Forum Infectious Diseases, 2021, 8, ofab221.	0.4	58
279	Epidemiological characteristics of the COVID-19 spring outbreak in Quebec, Canada: a population-based study. BMC Infectious Diseases, 2021, 21, 435.	1.3	5
280	Prevalence of Anti-SARS-CoV-2 Antibodies in PoznaÅ„, Poland, after the First Wave of the COVID-19 Pandemic. Vaccines, 2021, 9, 541.	2.1	10
281	Patterns and persistence of SARS-CoV-2 IgG antibodies in Chicago to monitor COVID-19 exposure. JCI Insight, 2021, 6, .	2.3	24
282	Low SARS-CoV-2 seroprevalence in the Austrian capital after an early governmental lockdown. Scientific Reports, 2021, 11, 10158.	1.6	13
283	The demography and characteristics of SARS-CoV-2 seropositive residents and staff of nursing homes for older adults in the Community of Madrid: the SeroSOS study. Age and Ageing, 2021, 50, 1038-1047.	0.7	29
284	Dynamics of SARS-CoV-2 with waning immunity in the UK population. Philosophical Transactions of the Royal Society B: Biological Sciences, 2021, 376, 20200274.	1.8	31
287	The impact of school reopening on the spread of COVID-19 in England. Philosophical Transactions of the Royal Society B: Biological Sciences, 2021, 376, 20200261.	1.8	41
288	Detecting infected asymptomatic cases in a stochastic model for spread of Covid-19: the case of Argentina. Scientific Reports, 2021, 11, 10024.	1.6	12
289	Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. The Lancet Global Health, 2021, 9, e598-e609.	2.9	193
290	Multisystem inflammatory syndrome in children occurred in one of four thousand children with severe acute respiratory syndrome coronavirus 2. Acta Paediatrica, International Journal of Paediatrics, 2021, 110, 2581-2583.	0.7	32
291	Insights into household transmission of SARS-CoV-2 from a population-based serological survey. Nature Communications, 2021, 12, 3643.	5.8	61
292	SARS-CoV-2 in eight municipalities of the Colombian tropics: high immunity, clinical and sociodemographic outcomes. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2022, 116, 139-147.	0.7	8
293	The prevalence of SARS-CoV-2 antibodies in triage-negative patients and staff of a fertility setting from lockdown release throughout 2020. Human Reproduction Open, 2021, 2021, hoab028.	2.3	2
294	Cross-Reactivity of Two SARS-CoV-2 Serological Assays in a Setting Where Malaria Is Endemic. Journal of Clinical Microbiology, 2021, 59, e0051421.	1.8	46
296	Sero-Prevalence of SARS-CoV-2 Antibodies in High-Risk Populations in Vietnam. International Journal of Environmental Research and Public Health, 2021, 18, 6353.	1.2	8

#	Article	IF	Citations
298	Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study. Scientific Reports, 2021, 11, 12930.	1.6	18
299	Monitoring the proportion of the population infected by SARS-CoV-2 using age-stratified hospitalisation and serological data: a modelling study. Lancet Public Health, The, 2021, 6, e408-e415.	4.7	54
300	Severe acute respiratory syndrome coronavirus 2 seroprevalence survey among 10,256 workers in Kuwait. Journal of Clinical Virology Plus, 2021, 1, 100017.	0.4	1
301	Prevalence of IgG antibodies induced by the SARSâ€COVâ€2 virus in asymptomatic adults in Nuevo Leon, Mexico. Journal of Medical Virology, 2021, 93, 5873-5879.	2.5	4
302	Insufficient type I IFN immunity underlies life-threatening COVID-19 pneumonia. Comptes Rendus - Biologies, 2021, 344, 19-25.	0.1	16
303	Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya. Nature Communications, 2021, 12, 3966.	5.8	40
304	Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany. JAMA Pediatrics, 2021, 175, 586.	3.3	124
305	High SARS-CoV-2 seroprevalence in children and adults in the Austrian ski resort of Ischgl. Communications Medicine, 2021, 1, 4.	1.9	36
306	Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 20201. Emerging Infectious Diseases, 2021, 27, 1598-1606.	2.0	38
307	Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort. Clinical Microbiology and Infection, 2021, 27, 1678-1684.	2.8	34
308	High Prevalence of Antiâ€“Severe Acute Respiratory Syndrome Coronavirus 2 (Antiâ€“SARS-CoV-2) Antibodies After the First Wave of Coronavirus Disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo: Results of a Cross-sectional Household-Based Survey. Clinical Infectious Diseases, 2022, 74, 882-890.	2.9	38
309	Dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: The evolution of a pandemic. International Journal of Infectious Diseases, 2021, 107, 116-120.	1.5	20
310	Multianalyte serology in home-sampled blood enables an unbiased assessment of the immune response against SARS-CoV-2. Nature Communications, 2021, 12, 3695.	5.8	32
311	Large variation in anti-SARS-CoV-2 antibody prevalence among essential workers in Geneva, Switzerland. Nature Communications, 2021, 12, 3455.	5.8	30
312	Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra. Lancet Regional Health - Europe, The, 2021, 5, 100119.	3.0	20
313	Seroprevalence of SARS-CoV-2 infection among children in Childrenâ€™s Hospital Zagreb during the initial and second wave of COVID-19 pandemic in Croatia. Biochemia Medica, 2021, 31, 283-294.	1.2	8
314	Prevalence of RT-qPCR-detected SARS-CoV-2 infection at schools: First results from the Austrian School-SARS-CoV-2 prospective cohort study. Lancet Regional Health - Europe, The, 2021, 5, 100086.	3.0	33
315	Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study. International Journal of Infectious Diseases, 2021, 107, 188-194.	1.5	19

#	Article	IF	Citations
316	Prevalence and determinants of SARS-CoV-2 vaccine hesitancy in Hong Kong: A population-based survey. Vaccine, 2021, 39, 3602-3607.	1.7	66
317	The solid organ transplant recipient with SARS-CoV-2 infection. Current Opinion in Organ Transplantation, 2021, 26, 412-418.	0.8	5
320	Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study. International Journal of Epidemiology, 2021, 50, 1458-1472.	0.9	75
321	Assessment of initial SARS-CoV-2 seroprevalence in the most affected districts in the municipality of SÃ£o Paulo, Brazil. Brazilian Journal of Infectious Diseases, 2021, 25, 101604.	0.3	5
322	Seroprevalence of anti-SARS-CoV-2 antibodies among school and daycare children and personnel: protocol for a cohort study in Montreal, Canada. BMJ Open, 2021, 11, e053245.	0.8	6
323	COVID-19 in schools: Mitigating classroom clusters in the context of variable transmission. PLoS Computational Biology, 2021, 17, e1009120.	1.5	34
325	Self-initiated behavioral change and disease resurgence on activity-driven networks. Physical Review E, 2021, 104, 014307.	0.8	13
326	Seroprevalence of severe acute respiratory syndrome coronavirus 2 in Slovenia: results of two rounds of a nationwide population study on a probability-based sample, challenges and lessons learned. Clinical Microbiology and Infection, 2021, 27, 1039.e1-1039.e7.	2.8	17
328	SARS-CoV2 IgG antibody: Seroprevalence among health care workers. Clinical Epidemiology and Global Health, 2021, 11, 100766.	0.9	9
329	Nationwide Seroprevalence of SARS-CoV-2 IgG Antibodies among Four Groups of Primary Health-Care Workers and Their Household Contacts 6 Months after the Initiation of the COVID-19 Vaccination Campaign in France: SeroPRIM Study Protocol. Pathogens, 2021, 10, 911.	1.2	6
331	Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People. Frontiers in Public Health, 2021, 9, 715192.	1.3	3
332	Childrenâ€™s role in the COVID-19 pandemic: a systematic review of early surveillance data on susceptibility, severity, and transmissibility. Scientific Reports, 2021, 11, 13903.	1.6	65
333	First surveillance of SARS-CoV-2 and organic tracers in community wastewater during post lockdown in Chennai, South India: Methods, occurrence and concurrence. Science of the Total Environment, 2021, 778, 146252.	3.9	57
335	Estimating the proportion and IgG antibody response to SARS-CoV-2 in individuals joining a central educational institute from different parts of India by Enzyme-linked immunosorbent assay (ELISA) based serology. Medical Journal Armed Forces India, 2021, 77, S366-S372.	0.3	1
336	Epidemiology and Risk of Coronavirus Disease 2019 Among Travelers at Airport and Port Quarantine Stations Across Japan: A Nationwide Descriptive Analysis and an Individually Matched Case-Control Study. Clinical Infectious Diseases, 2022, 74, 1614-1622.	2.9	3
337	Serologic response to SARS-CoV-2 in an African population. Scientific African, 2021, 12, e00802.	0.7	16
338	Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adults. Communications Medicine, 2021, 1, .	1.9	19
339	Risk of infection and transmission of SARS-CoV-2 among children and adolescents in households, communities and educational settings: A systematic review and meta-analysis. Journal of Global Health, 2021, 11, 05013.	1.2	57

#	Article	IF	Citations
341	SARS-CoV-2 seroprevalence in healthcare workers of a Swiss tertiary care centre at the end of the first wave: a cross-sectional study. BMJ Open, 2021, 11, e049232.	0.8	10
342	A National Framework to Improve Mortality, Morbidity, and Disparities Data for COVID-19 and Other Large-Scale Disasters. American Journal of Public Health, 2021, 111, S93-S100.	1.5	11
343	Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study. PLoS ONE, 2021, 16, e0254516.	1.1	10
344	Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance. Clinical Microbiology and Infection, 2021, 27, 1695.e7-1695.e12.	2.8	38
345	Prevalence of SARS-CoV-2 antibodies in Denmark: nationwide, population-based seroepidemiological study. European Journal of Epidemiology, 2021, 36, 715-725.	2.5	40
346	SARS-CoV-2 PCR positivity rate and seroprevalence of related antibodies among a sample of patients in Cairo: Pre-wave 2 results of a screening program in a university hospital. PLoS ONE, 2021, 16, e0254581.	1.1	5
347	Variation in SARS-CoV-2 seroprevalence across districts, schools and classes: baseline measurements from a cohort of primary and secondary school children in Switzerland. BMJ Open, 2021, 11, e047483.	0.8	15
348	Evaluation of SARS-CoV-2 RNA quantification by RT-LAMP compared to RT-qPCR. Journal of Infection and Chemotherapy, 2021, 27, 1068-1071.	0.8	11
349	Determinants of having severe acute respiratory syndrome coronavirus 2 neutralizing antibodies in Egypt. Influenza and Other Respiratory Viruses, 2021, 15, 750-756.	1.5	3
350	Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a population-based study. The Lancet Global Health, 2021, 9, e925-e931.	2.9	65
351	The burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population: Results from a statewide sentinel-based population survey in Karnataka, India. International Journal of Infectious Diseases, 2021, 108, 27-36.	1.5	21
352	Social Distancing during COVID-19 Pandemic among Inflammatory Bowel Disease Patients. Journal of Clinical Medicine, 2021, 10, 3689.	1.0	3
353	ESTIMATION OF SARS-COV-2 SPECIFIC ANTIBODIES SEROPREVALENCE IN HEALTHCARE WORKERS IN DISTRICT UDAIPUR, INDIA. , 2021, , 61-63.		0
354	Slow Spread of SARS-CoV-2 in Southern Brazil Over a 6-Month Period: Report on 8 Sequential Statewide Serological Surveys Including 35â€‰611 Participants. American Journal of Public Health, 2021, 111, 1542-1550.	1.5	6
355	Saving lives during the COVID-19 pandemic: the benefits of the first Swiss lockdown. Swiss Journal of Economics and Statistics, 2021, 157, 4.	0.5	3
359	Acceptability of COVID-19 Certificates: A Qualitative Study in Geneva, Switzerland, in 2020. Frontiers in Public Health, 2021, 9, 682365.	1.3	4
360	Efficiency of National Taskforce for Combating the Coronavirus (COVID-19) Protocol using real-time PCR testing in health facilities over a period of 8-weeks. Journal of Infection and Public Health, 2021, 14, 1045-1050.	1.9	1
361	Positive anti-SARS-CoV-2 rapid serological test results among asymptomatic blood donors. Transfusion Clinique Et Biologique, 2022, 29, 24-30.	0.2	5

#	Article	IF	Citations
362	SARSâ€CoVâ€2 infection as a trigger of humoral response against apolipoprotein Aâ€1. European Journal of Clinical Investigation, 2021, 51, e13661.	1.7	10
363	A particle swarm optimization approach for predicting the number of COVID-19 deaths. Scientific Reports, 2021, 11, 16587.	1.6	13
364	Serological prevalence of SARS-CoV-2 infection and associated factors in healthcare workers in a â€œnon-COVIDâ€•hospital in Mexico City. PLoS ONE, 2021, 16, e0255916.	1.1	8
365	Age-dependent seroprevalence of SARS-CoV-2 antibodies in school-aged children from areas with low and high community transmission. European Journal of Pediatrics, 2022, 181, 571-578.	1.3	23
366	Describing cognitive function and psychosocial outcomes of COVID-19 survivors: A cross-sectional analysis. Journal of the American Association of Nurse Practitioners, 2022, 34, 499-508.	0.5	9
367	COVID-19 spread, detection, and dynamics in Bogota, Colombia. Nature Communications, 2021, 12, 4726.	5.8	18
370	Sustained seroprevalence of SARS-CoV-2 antibodies one year after infection: one of the first COVID-19 cluster cases in Bosnia and Herzegovina. Bosnian Journal of Basic Medical Sciences, 2021, , .	0.6	4
371	Seroprevalence and risk factors of SARS-CoV-2 infection in an urban informal settlement in Nairobi, Kenya, December 2020. F1000Research, 2021, 10, 853.	0.8	7
372	Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5Âmonths after pandemic arrival. BMC Infectious Diseases, 2021, 21, 835.	1.3	4
373	Analysis of the Behaviour of Immunoglobulin G Antibodies in Children and Adults Convalescing From Severe Acute Respiratory Syndrome-Coronavirus-2 Infection. Frontiers in Pediatrics, 2021, 9, 671831.	0.9	4
374	Rapid and Laboratory SARS-CoV-2 Antibody Testing in High-Risk Hospital Associated Cohorts of Unknown COVID-19 Exposure, a Validation and Epidemiological Study After the First Wave of the Pandemic. Frontiers in Medicine, 2021, 8, 642318.	1.2	2
375	COVID-19 Case Age Distribution: Correction for Differential Testing by Age. Annals of Internal Medicine, 2021, 174, 1430-1438.	2.0	19
376	SARS-CoV-2 Seroprevalence among the Health Care Staff of an Ophthalmological Reference Centre, a Cross Sectional Study. Ophthalmic Epidemiology, 2022, 29, 483-490.	0.8	2
377	Bayesian workflow for disease transmission modeling in Stan. Statistics in Medicine, 2021, 40, 6209-6234.	0.8	26
378	Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys. International Journal of Infectious Diseases, 2021, 112, 269-277.	1.5	20
379	Vulnerable patients forgo health care during the first wave of the Covid-19 pandemic. Preventive Medicine, 2021, 150, 106696.	1.6	27
380	Seroprevalence of SARS-CoV-2 antibodies among homeless people living rough, in shelters and squats: A large population-based study in France. PLoS ONE, 2021, 16, e0255498.	1.1	21
381	SARS-CoV-2 Antibody Rapid Tests: Valuable Epidemiological Tools in Challenging Settings. Microbiology Spectrum, 2021, 9, e0025021.	1.2	7

#	Article	IF	Citations
382	SARS-CoV-2 seroprevalence and associated factors in Manaus, Brazil: baseline results from the DETECTCoV-19 cohort study. International Journal of Infectious Diseases, 2021, 110, 141-150.	1.5	32
383	Assessment of SARS-CoV-2 Anti-Spike IgG Antibody in Women and Children in Madinah, Saudi Arabia: A Single-Center Study. International Journal of Environmental Research and Public Health, 2021, 18, 9971.	1.2	10
384	Guillain-BarrÃ© syndrome after SARS-CoV-2 infection in an international prospective cohort study. Brain, 2021, 144, 3392-3404.	3.7	39
385	SARS-CoV-2 transmission dynamics in Belarus in 2020 revealed by genomic and incidence data analysis. Communications Medicine, 2021, 1, .	1.9	7
386	Non-occupational and occupational factors associated with specific SARS-CoV-2 antibodies among hospital workers â€“ A multicentre cross-sectional study. Clinical Microbiology and Infection, 2021, 27, 1336-1344.	2.8	32
387	Socioeconomic position and the COVID-19 care cascade from testing to mortality in Switzerland: a population-based analysis. Lancet Public Health, The, 2021, 6, e683-e691.	4.7	85
388	Pediatric COVID-19: Immunopathogenesis, Transmission and Prevention. Vaccines, 2021, 9, 1002.	2.1	16
391	SARS-CoV-2 epidemiology, prevention, risk factors, evaluation, diagnosis, management and vaccines. Osteopathic Family Physician, 2021, 13, .	0.2	0
392	SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar. Scientific Reports, 2021, 11, 18182.	1.6	49
393	Lecithinized superoxide dismutase in the past and in the present: Any role in the actual pandemia of COVID-19?. Biomedicine and Pharmacotherapy, 2021, 141, 111922.	2.5	8
394	National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic. Public Health, 2021, 198, 102-105.	1.4	4
395	Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys. PLoS Computational Biology, 2021, 17, e1009436.	1.5	21
396	Seroprevalence of SARS-CoV-2 antibodies among hospital staff in rural Central Fukushima, Japan: A historical cohort study. International Immunopharmacology, 2021, 98, 107884.	1.7	16
397	Seroprevalence of Immunoglobulin-G Antibody Among Confirm Cases of COVID-19. Cureus, 2021, 13, e17956.	0.2	1
398	Robust innate responses to SARS-CoV-2 in children resolve faster than in adults without compromising adaptive immunity. Cell Reports, 2021, 37, 109773.	2.9	58
399	Saliva SARS-CoV-2 Antibody Prevalence in Children. Microbiology Spectrum, 2021, 9, e0073121.	1.2	25
400	Follicular Helper T Cells in the Immunopathogenesis of SARS-CoV-2 Infection. Frontiers in Immunology, 2021, 12, 731100.	2.2	32
401	Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study). Vaccine, 2021, 39, 5376-5384.	1.7	9

#	Article	IF	Citations
402	Comparison of SARS-CoV-2 serological assays for use in epidemiological surveillance in Scotland. Journal of Clinical Virology Plus, 2021, 1, 100028.	0.4	2
403	Comparing Immunoassays for SARS-CoV-2 Antibody Detection in Patients with and without Laboratory-Confirmed SARS-CoV-2 Infection. Journal of Clinical Microbiology, 2021, 59, e0138121.	1.8	16
404	Factors associated with decision making on COVID-19 vaccine acceptance among college students in South Carolina. Psychology, Health and Medicine, 2022, 27, 150-161.	1.3	38
405	Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020. BMJ Open, 2021, 11, e053791.	0.8	8
406	Prevalence and Transmission of Severe Acute Respiratory Syndrome Coronavirus Type 2 in Childcare Facilities: A Longitudinal Study. Journal of Pediatrics, 2021, 237, 136-142.	0.9	10
407	A Bayesian estimate of the early COVID-19 infection fatality ratio in Brazil based on a random seroprevalence survey. International Journal of Infectious Diseases, 2021, 111, 190-195.	1.5	12
408	Prevalence, Distribution and IgG Antibody Levels Associated with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Health-System and Community-Based Employees and Patients. American Journal of the Medical Sciences, 2022, 363, 18-24.	0.4	2
409	Seroprevalence and risk factors for SARS-CoV-2 Infection in selected urban areas in Ethiopia: a cross-sectional evaluation during July 2020. International Journal of Infectious Diseases, 2021, 111, 179-185.	1.5	15
410	A three-phase population based sero-epidemiological study: Assessing the trend in prevalence of SARS-CoV-2 during COVID-19 pandemic in Jordan. One Health, 2021, 13, 100292.	1.5	26
411	The sudden appearance of SARS-CoV-2. , 2022, , 1-21.		1
413	Prevalence and Longevity of SARS-CoV-2 Antibodies Among Health Care Workers. Open Forum Infectious Diseases, 2021, 8, ofab015.	0.4	4
414	Seroprevalence of SARS-CoV-2 antibodies in the poorest region of Brazil: results from a population-based study. Epidemiology and Infection, 2021, 149, e130.	1.0	5
415	Multisystem inflammatory syndrome in children associated with Coronavirus Disease-2019: An overview. Archives of Medicine and Health Sciences, 2021, 9, 101.	0.0	0
416	Characteristics of Three Different Chemiluminescence Assays for Testing for SARS-CoV-2 Antibodies. Disease Markers, 2021, 2021, 1-13.	0.6	17
417	COVID-19 seropositivity among non-medical frontline office staff from two cities in Rajasthan, India. Journal of Family Medicine and Primary Care, 2021, 10, 2400.	0.3	2
418	Seroprevalence of SARS-CoV-2 antibodies in over 6000 healthcare workers in Spain. International Journal of Epidemiology, 2021, 50, 400-409.	0.9	50
419	Serological investigation of asymptomatic cases of SARS-CoV-2 infection reveals weak and declining antibody responses. Emerging Microbes and Infections, 2021, 10, 905-912.	3.0	16
420	Correlation of SARS-CoV-2 Serology and Clinical Phenotype Amongst Hospitalised Children in a Tertiary Childrenâ€™s Hospital in India. Journal of Tropical Pediatrics, 2021, 67, .	0.7	13

#	Article	IF	Citations
421	Low Prevalence of Antibodies to SARS-CoV-2 and Undetectable Viral Load in Seropositive Blood Donors from South-Eastern Italy. Acta Haematologica, 2021, 144, 580-584.	0.7	9
422	A comprehensive review and update on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Coronavirus disease 2019 (COVID-19): what do we know now in 2021?. Archives of Medical Sciences Atherosclerotic Diseases, 2021, 6, 5-13.	0.5	13
423	Seroprevalence of Anti-SARS-CoV-2 Antibodies in Iquitos, Loreto, Peru. SSRN Electronic Journal, 0, , .	0.4	4
425	Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey. International Journal of Epidemiology, 2022, 51, 404-417.	0.9	29
426	SARS-CoV-2 outbreak in a synagogue community: longevity and strength of anti-SARS-CoV-2 IgG responses. Epidemiology and Infection, 2021, 149, e153.	1.0	0
430	COVID-19 and Pediatric Lung Disease: A South African Tertiary Center Experience. Frontiers in Pediatrics, 2020, 8, 614076.	0.9	10
431	COVID-19 in Children and COVID-19 Vaccines. , 2021, , 297-303.		0
432	Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: a community-based cross-sectional study, August 2020. Journal of Family Medicine and Primary Care, 2021, 10, 1479.	0.3	3
433	Household Transmission of SARS-CoV-2. JAMA Network Open, 2020, 3, e2031756.	2.8	568
434	Microscopyâ€based assay for semiâ€quantitative detection of SARSâ€CoVâ€2 specific antibodies in human sera. BioEssays, 2021, 43, e2000257.	1.2	22
435	Seroprevalence of SARSâ€CoVâ€2 infections among children visiting a hospital. Pediatric Investigation, 2020, 4, 236-241.	0.6	7
437	Underdetection of cases of COVID-19 in France threatens epidemic control. Nature, 2021, 590, 134-139.	13.7	196
438	Comparison of Estimated Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Through Commercial Laboratory Residual Sera Testing and a Community Survey. Clinical Infectious Diseases, 2021, 73, e3120-e3123.	2.9	14
439	SARS-Cov-2 viral and serological screening of staff in 31 European fertility units. Human Reproduction Open, 2020, 2020, hoaa056.	2.3	5
440	Severe Acute Respiratory Syndrome Coronavirus 2 Serosurveillance in a Patient Population Reveals Differences in Virus Exposure and Antibody-Mediated Immunity According to Host Demography and Healthcare Setting. Journal of Infectious Diseases, 2021, 223, 971-980.	1.9	20
441	Demographic and occupational determinants of anti-SARS-CoV-2 IgG seropositivity in hospital staff. Journal of Public Health, 2022, 44, 234-245.	1.0	60
442	A Risk Model of Admitting Patients With Silent SARS-CoV-2 Infection to Surgery and Development of Severe Postoperative Outcomes and Death. Annals of Surgery, 2021, 273, 208-216.	2.1	3
443	The scale and dynamics of COVID-19 epidemics across Europe. Royal Society Open Science, 2020, 7, 201726.	1.1	21

#	Article	IF	Citations
534	Effective immunity and second waves: a dynamic causal modelling study. Wellcome Open Research, 2020, 5, 204.	0.9	6
535	Seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar, northern India â€“ A cross-sectional study. PLoS ONE, 2020, 15, e0239303.	1.1	22
536	Post lockdown COVID-19 seroprevalence and circulation at the time of delivery, France. PLoS ONE, 2020, 15, e0240782.	1.1	26
537	Effectiveness of infection-containment measures on SARS-CoV-2 seroprevalence and circulation from May to July 2020, in Milan, Italy. PLoS ONE, 2020, 15, e0242765.	1.1	10
538	An original multiplex method to assess five different SARS-CoV-2 antibodies. Clinical Chemistry and Laboratory Medicine, 2021, 59, 971-978.	1.4	15
539	Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network â€" 12 States, Aprilâ€"August 2020. Morbidity and Mortality Weekly Report, 2020, 69, 1762-1766.	9.0	120
540	Breastmilk: A Source of SARS-CoV-2 Specific IgA Antibodies. SSRN Electronic Journal, 0, , .	0.4	7
541	Strategies for Infection Control and Prevalence of Anti-SARS-CoV-2 IgG Antibodies in 4,554 Employees of a University Hospital in Munich, Germany. SSRN Electronic Journal, 0, , .	0.4	2
542	Reinfection with SARS-CoV-2: Discrete SIR (Susceptible, Infected, Recovered) Modeling Using Empirical Infection Data. JMIR Public Health and Surveillance, 2020, 6, e21168.	1.2	15
543	SARS-CoV-2/COVID-19 Testing: The Tower of Babel. Acta Biomedica, 2020, 91, e2020144.	0.2	4
544	Infection fatality rate of COVID-19 inferred from seroprevalence data. Bulletin of the World Health Organization, 2021, 99, 19-33F.	1.5	278
545	Immunity certification for COVID-19: ethical considerations. Bulletin of the World Health Organization, 2021, 99, 155-161.	1.5	43
546	Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020. Eurosurveillance, 2020, 25, .	3.9	53
547	Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. Eurosurveillance, 2020, 25, .	3.9	64
548	SARS-CoV-2 Seroprevalence among Healthcare, First Response, and Public Safety Personnel, Detroit Metropolitan Area, Michigan, USA, Mayâ€"June 2020. Emerging Infectious Diseases, 2020, 26, 2863-2871.	2.0	59
549	Transmission of SARS-CoV-2 by Children. Deutsches Ärzteblatt International, 2020, 117, 553-560.	0.6	30
550	Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea. Journal of Korean Medical Science, 2020, 35, e311.	1.1	31
551	Clinical Epidemiology of Coronavirus Disease 2019:Defined on Current Research. Global Clinical and Translational Research, 2020, , 54-72.	0.4	2

#	Article	IF	Citations
552	The enigmatic COVID-19 pandemic. Indian Journal of Medical Research, 2020, 152, 1.	0.4	5
553	Quantifying antibody kinetics and RNA detection during early-phase SARS-CoV-2 infection by time since symptom onset. ELife, 2020, 9, .	2.8	74
554	Analysing Long-Term Socio-Economic Impacts of COVID-19 across Diverse African Contexts. SSRN Electronic Journal, 0, , .	0.4	0
555	ESTIMATION OF SARS COV 2 SPECIFIC ANTIBODIES SEROPREVALENCE IN HEALTHCARE WORKERS IN DISTRICT UDAIPUR, INDIA. , 2021, , 31-33.		0
556	OutbreakFlow: Model-based Bayesian inference of disease outbreak dynamics with invertible neural networks and its application to the COVID-19 pandemics in Germany. PLoS Computational Biology, 2021, 17, e1009472.	1.5	19
557	Longitudinal SARSâ€CoVâ€2 seroprevalence in Portugal and antibody maintenance 12 months after infection. European Journal of Immunology, 2022, 52, 149-160.	1.6	15
559	Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic. Cancer Investigation, 2022, 40, 115-123.	0.6	20
560	Non-Invasive Antibody Assessment in Saliva to Determine SARS-CoV-2 Exposure in Young Children. Frontiers in Immunology, 2021, 12, 753435.	2.2	13
562	Update on the COVID-19 Vaccine Research Trends: A Bibliometric Analysis. Infection and Drug Resistance, 2021, Volume 14, 4237-4247.	1.1	17
563	Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study. Scandinavian Journal of Public Health, 2022, 50, 124-135.	1.2	22
565	Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects. Cellular and Molecular Immunology, 2022, 19, 150-157.	4.8	43
566	Representative estimates of COVID-19 infection fatality rates from four locations in India: cross-sectional study. BMJ Open, 2021, 11, e050920.	0.8	7
569	SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon. Nature Communications, 2021, 12, 5851.	5.8	38
570	Head-to-head evaluation of seven different seroassays including direct viral neutralisation in a representative cohort for SARS-CoV-2. Journal of General Virology, 2021, 102, .	1.3	21
571	SARS-CoV-2 seroprevalence in children and their family members, Julyâ€“October 2020, Brussels. European Journal of Pediatrics, 2022, 181, 1009-1016.	1.3	4
572	Half-Year Longitudinal Seroprevalence of SARS-CoV-2-Antibodies and Rule Compliance in German Hospital Employees. International Journal of Environmental Research and Public Health, 2021, 18, 10972.	1.2	5
573	COVID-19 and the Gastrointestinal Tract. Gastroenterology Insights, 2021, 12, 394-404.	0.7	4
574	The Influence of Helminth Immune Regulation on COVID-19 Clinical Outcomes: Is it Beneficial or Detrimental?. Infection and Drug Resistance, 2021, Volume 14, 4421-4426.	1.1	12

#	Article	IF	Citations
575	Quantifying previous SARS-CoV-2 infection through mixture modelling of antibody levels. Nature Communications, 2021, 12, 6196.	5.8	15
576	A Serological Snapshot of COVID-19 Initial Stages in Israel by a 6-Plex Antigen Array. Microbiology Spectrum, 2021, 9, e0087021.	1.2	2
577	Probability-Based Estimates of Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Detection Fraction, Utah, USA. Emerging Infectious Diseases, 2021, 27, 2786-2794.	2.0	4
578	Health-related biological and non-biological consequences of forgoing healthcare for economic reasons. Preventive Medicine Reports, 2021, 24, 101602.	0.8	5
579	Antibody response among nucleic acid amplification test confirmed COVID-19-positive patients: A cross-sectional study. Journal of Marine Medical Society, 2020, .	0.0	0
588	Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021. Eurosurveillance, 2021, 26, .	3.9	44
590	Prevalence evolution of SARS-CoV-2 infection in the city of SÃ£o Paulo, 2020â€“2021. Revista De Saude Publica, 2021, 55, 62.	0.7	2
591	A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases. Journal of Autoimmunity, 2021, 125, 102743.	3.0	45
597	Antibody Reactivity Against SARS-CoV-2 in Adults from the Vancouver Metropolitan Area, Canada. SSRN Electronic Journal, 0, , .	0.4	0
598	Past, present, and future of COVID-19: a review. Brazilian Journal of Medical and Biological Research, 2020, 53, e10475.	0.7	9
599	PREVALENCE OF MARKERS OF SARS-COV-2 INFECTION AMONG RESIDENTS OF KYIV REGION AT THE BEGINNING OF THE COVID-19 EPIDEMIC â€“ FIRST RESULTS IN UKRAINE. Journal of the National Academy of Medical Sciences of Ukraine, 2021, , 118-132.	0.1	1
600	A cross-sectional investigation of SARS-CoV-2 seroprevalence and associated risk factors in children and adolescents in the United States. PLoS ONE, 2021, 16, e0259823.	1.1	15
601	The seroprevalence of SARS-CoV-2 during the first wave in Europe 2020: A systematic review. PLoS ONE, 2021, 16, e0250541.	1.1	21
602	Pericardial and myocardial involvement after SARS-CoV-2 infection: a cross-sectional descriptive study in healthcare workers. Revista Espanola De Cardiologia (English Ed), 2022, 75, 734-746.	0.4	14
603	Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola. BMC Infectious Diseases, 2021, 21, 1131.	1.3	10
604	Development of at-home sample collection logistics for large-scale seroprevalence studies. PLoS ONE, 2021, 16, e0258516.	1.1	2
605	Inferring the COVID-19 infection fatality rate in the community-dwelling population: a simple Bayesian evidence synthesis of seroprevalence study data and imprecise mortality data. Epidemiology and Infection, 2021, 149, .	1.0	5
607	SARS-CoV-2 IgG seropositivity in a cohort of 449 non-hospitalized individuals during Spanish COVID-19 lockdown. Scientific Reports, 2021, 11, 21612.	1.6	4

#	Article	IF	Citations
608	Retrospective epidemiology of the SARS-CoV-2 (and COVID-19) epidemic among 27 Brazilian cities. Journal of Clinical Virology Plus, 2021, 1, 100053.	0.4	2
616	Effective immunity and second waves: a dynamic causal modelling study. Wellcome Open Research, 2020, 5, 204.	0.9	7
617	Designing a multi-layered surveillance approach to detecting SARS-CoV-2: A modelling study. Wellcome Open Research, 0, 5, 218.	0.9	0
618	Predicting the dynamics of Covid-19 incidence and planning preventive vaccination measures for Moscow population based on mathematical modeling. Zhurnal Mikrobiologii Epidemiologii I Immunobiologii, 2020, 97, 289-302.	0.3	5
628	Prevalence of SARS-COVID-19 serum IgG antibodies amongst staff on an acute surgical unit. British Journal of Surgery, 2020, 107, e576-e577.	0.1	1
629	Seroprevalence of IgM and IgG Antibodies against SARS-CoV-2 in Asymptomatic People in Wuhan: Data from a General Hospital Near South China Seafood Wholesale Market during March to April in 2020. Biomedical and Environmental Sciences, 2021, 34, 743-749.	0.2	0
631	IgG seroprevalence of COVIDâ€19 among people living with HIV or at high risk of HIV in southâ€west Germany: A seroprevalence study. HIV Medicine, 2021, , .	1.0	3
632	Seroprevalence of SARS-CoV-2 Antibodies Among Children in School and Day Care in Montreal, Canada. JAMA Network Open, 2021, 4, e2135975.	2.8	33
633	Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK). Thorax, 2022, 77, 900-912.	2.7	47
634	The Differences in the Level of Anti-SARS-CoV-2 Antibodies after mRNA Vaccine between Convalescent and Non-Previously Infected People Disappear after the Second Doseâ€"Study in Healthcare Workers Group in Poland. Vaccines, 2021, 9, 1402.	2.1	3
635	Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020. Pathogens, 2021, 10, 1505.	1.2	1
636	SARS-CoV-2 PCR and antibody positivity among school staff at the beginning and end of the first school term. BMC Public Health, 2021, 21, 2070.	1.2	3
637	Design of a population-based longitudinal cohort study of SARS-CoV-2 incidence and prevalence among adults in the San Francisco Bay Area. Annals of Epidemiology, 2022, 67, 81-100.	0.9	5
638	Prevalence of SARS-CoV-2 antibodies in hemodialysis patients in Senegal: a multicenter cross-sectional study. BMC Nephrology, 2021, 22, 384.	0.8	9
639	Community-Based Seroprevalence of SARS-CoV-2 Antibodies following the First Wave of the COVID-19 Pandemic in Jazan Province, Saudi Arabia. International Journal of Environmental Research and Public Health, 2021, 18, 12451.	1.2	9
640	Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020. Global Epidemiology, 2021, 3, 100068.	0.6	30
641	Cohort profile: Actionable Register of Geneva Outpatients and inpatients with SARS-CoV-2 (ARGOS). BMJ Open, 2021, 11, e048946.	0.8	9
642	Adjusting COVID-19 Seroprevalence Survey Results to Account for Test Sensitivity and Specificity. American Journal of Epidemiology, 2022, 191, 681-688.	1.6	5

#	Article	IF	Citations
643	SARS-CoV-2 IgG Antibody and its Clinical Correlates in Convalescent Plasma Donors: An Indian Experience. Indian Journal of Clinical Biochemistry, 2022, 37, 423-431.	0.9	3
644	The utility of SARSâ€CoVâ€2â€specific serology in COVIDâ€19 diagnosis. Australian and New Zealand Journal of Public Health, 2021, 45, 616-621.	0.8	0
645	Seroprevalence of SARS-CoV-2 Infection in the Colombo Municipality Region, Sri Lanka. Frontiers in Public Health, 2021, 9, 724398.	1.3	8
646	Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study. BMJ Open, 2021, 11, e053201.	0.8	11
647	Immunocompromised children and young people are at no increased risk of severe COVID-19. Journal of Infection, 2022, 84, 31-39.	1.7	29
648	Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020. PLoS Neglected Tropical Diseases, 2021, 15, e0009945.	1.3	9
649	A global assessment of the impact of school closure in reducing COVID-19 spread. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2022, 380, 20210124.	1.6	13
650	Analysis of case fatality rate of SARS-CoV-2 infection in the Spanish Autonomous Communities between March and May 2020. PLoS ONE, 2021, 16, e0260769.	1.1	2
651	Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximab. RMD Open, 2021, 7, e001711.	1.8	6
652	The Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A seroprevalence study, June to July 2020. Eurosurveillance, 2021, 26, .	3.9	8
653	Contrasting SARS-CoV-2 epidemics in Singapore: cohort studies in migrant workers and the general population. International Journal of Infectious Diseases, 2022, 115, 72-78.	1.5	5
655	SARS-CoV-2 seroprevalence in Aden, Yemen: a population-based study. International Journal of Infectious Diseases, 2022, 115, 239-244.	1.5	14
656	SARS-CoV-2 Seroprevalence before Delta Variant Surge, Chattogram, Bangladesh, Marchâ€“June 2021. Emerging Infectious Diseases, 2022, 28, 429-431.	2.0	13
657	Understanding the Prevalence and Geographic Heterogeneity of SARS-CoV-2 Infection: Findings of the First Serosurvey in Uttar Pradesh, India. Journal of Epidemiology and Global Health, 2021, 11, 364-376.	1.1	0
658	Immunogenicity after CoronaVac vaccination. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2021, 67, 1403-1408.	0.3	13
659	Current challenges of severe acute respiratory syndrome coronavirus 2 seroprevalence studies among blood donors: A scoping review. Vox Sanguinis, 2022, 117, 476-487.	0.7	5
661	SARS-CoV-2 seroprevalence in Portugal following the third epidemic wave: results of the second National Serological Survey (ISN2COVID-19). Infectious Diseases, 2022, 54, 418-424.	1.4	15
662	Seroprevalence, spatial distribution, and social determinants of SARS-CoV-2 in three urban centers of Chile. BMC Infectious Diseases, 2022, 22, 99.	1.3	17

#	Article	IF	Citations
663	SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey. BMC Infectious Diseases, 2022, 22, 42.	1.3	13
664	SARS-CoV-2 Seroprevalence Among Whole Blood Donors During First Wave of Covid-19 Pandemic in India. Indian Journal of Hematology and Blood Transfusion, 2022, , 1-10.	0.3	3
665	SARS-CoV-2 sero-prevalence in the workforces of three large workplaces in South Wales: a sero-epidemiological study. BMC Public Health, 2022, 22, 162.	1.2	2
666	Seroprevalence of SARS-CoV-2 antibodies and knowledge, attitude and practice toward COVID-19 in the Republic of Srpska-Bosnia & Herzegovina: A population-based study. PLoS ONE, 2022, 17, e0262738.	1.1	4
667	Long COVID symptoms and duration in SARS-CoV-2 positive children â€" a nationwide cohort study. European Journal of Pediatrics, 2022, 181, 1597-1607.	1.3	164
668	Prevalence of antibodies against SARS-CoV-2 among pregnant women in Norway during the period December 2019 through December 2020. Epidemiology and Infection, 2022, 150, 1-9.	1.0	4
669	Specchio-COVID19 cohort study: a longitudinal follow-up of SARS-CoV-2 serosurvey participants in the canton of Geneva, Switzerland. BMJ Open, 2022, 12, e055515.	0.8	12
670	Review of Clinical Performance of Serology Based Commercial Diagnostic Assays for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies. Viral Immunology, 2022, 35, 82-111.	0.6	4
671	Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort. BMC Infectious Diseases, 2022, 22, 41.	1.3	31
672	Immunoglobulin-G antibodies against severe acute respiratory syndrome â€" coronavirus-2 among health-care workers: A serosurveillance study from India. International Journal of Applied & Basic Medical Research, 2022, 12, 18.	0.2	1
673	Strategies for COVID-19 vaccination under a shortage scenario: a geo-stochastic modelling approach. Scientific Reports, 2022, 12, 1603.	1.6	6
674	Geospatial model of COVID-19 spreading and vaccination with event Gillespie algorithm. Nonlinear Dynamics, 2022, 109, 239-248.	2.7	2
675	Development of a quantitative COVID-19 multiplex assay and its use for serological surveillance in a low SARS-CoV-2 incidence community. PLoS ONE, 2022, 17, e0262868.	1.1	6
676	Epidemiology of SARS-CoV-2 Infection in Italy Using Real-World Data: Methodology and Cohort Description of the Second Phase of Web-Based EPICOVID19 Study. International Journal of Environmental Research and Public Health, 2022, 19, 1274.	1.2	4
677	Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Children. Infectious Disease Clinics of North America, 2022, 36, 435-479.	1.9	11
678	Rapid biosensing SARS-CoV-2 antibodies in vaccinated healthy donors. Biosensors and Bioelectronics, 2022, 204, 114054.	5.3	15
679	Nationally representative SARS-CoV-2 antibody prevalence estimates after the first epidemic wave in Mexico. Nature Communications, 2022, 13, 589.	5.8	29
681	What drives innovation? Lessons from COVID-19 R&D. Journal of Health Economics, 2022, 82, 102591.	1.3	23

#	Article	IF	Citations
682	Seroprevalence of SARS-CoV-2 antibodies in social housing areas in Denmark. BMC Infectious Diseases, 2022, 22, 143.	1.3	12
684	Characteristics of Symptomatic and Asymptomatic Patients With COVID-19 and Seroprevalence of anti-SARS-CoV-2 Antibodies in ZavidoviÄ‡i, Bosnia and Herzegovina. European Journal of Medical and Health Sciences, 2022, 4, 80-84.	0.1	0
685	Incidence of SARS-CoV-2 infection in a cohort of workers from the University of Porto, Portugal. Infectious Diseases, 2022, , 1-7.	1.4	0
686	Seroprevalence of SARS-CoV-2 Antibodies and its Risk Factors in the North-West of Iran: A Population-Based Cross-Sectional Study. Open Public Health Journal, 2022, 15, .	0.1	0
687	Monitoring of SARS-CoV-2 seroprevalence among primary healthcare patients in the Barcelona Metropolitan Area: the SeroCAP sentinel network protocol. BMJ Open, 2022, 12, e053237.	0.8	2
688	Forgoing healthcare during the COVID-19 pandemic in Geneva, Switzerland â€“ A cross-sectional population-based study. Preventive Medicine, 2022, 156, 106987.	1.6	9
689	Infection Control Measures and Prevalence of SARS-CoV-2 IgG among 4,554 University Hospital Employees, Munich, Germany. Emerging Infectious Diseases, 2022, 28, 572-581.	2.0	10
690	Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study. The Lancet Regional Health Americas, 2022, 9, 100195.	1.5	17
691	CORD-19: The Covid-19 Open Research Dataset. ArXiv Org, 2020, , .	1.2	1
692	Seroprevalence of SARS-CoV-2 antibodies in patients with autoimmune inflammatory rheumatic diseases. Clinical and Experimental Rheumatology, 0, , .	0.4	2
693	Seroprevalence of SARS-CoV-2 Antibodies in Children and Adolescents: Results From a Population-Based Survey in 10 Colombian Cities. Global Pediatric Health, 2022, 9, 2333794X2210853.	0.3	5
694	COVIDâ€19 and children: medical impact and collateral damage. Microbial Biotechnology, 2022, 15, 1035-1049.	2.0	4
695	Emerging complications of COVID-19 in a subset of Indian population: a pathological review with clinico-radiological case scenarios. Egyptian Journal of Radiology and Nuclear Medicine, 2022, 53, .	0.3	0
696	SARS-CoV-2 Antibody Seroprevalence in Patients With Cancer on Systemic Antineoplastic Treatment in the First Wave of the COVID-19 Pandemic in Portugal. Cureus, 2022, 14, e22428.	0.2	0
697	Trends in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Seroprevalence in Massachusetts Estimated from Newborn Screening Specimens. Clinical Infectious Diseases, 2022, 75, e105-e113.	2.9	3
698	The Corona Immunitas Digital Follow-Up eCohort to Monitor Impacts of the SARS-CoV-2 Pandemic in Switzerland: Study Protocol and First Results. International Journal of Public Health, 2022, 67, 1604506.	1.0	16
699	SARS-CoV-2 seroprevalence in the city of Puerto Madryn: Underdiagnosis and relevance of children in the pandemic. PLoS ONE, 2022, 17, e0263679.	1.1	6
700	Seroprevalence of SARS-Cov-2 IgG antibodies in patients at a single center in Saudi Arabia. Annals of Saudi Medicine, 2022, 42, 69-74.	0.5	0

#	Article	IF	Citations
701	Seroprevalence of SARS-CoV-2 antibodies, associated factors, experiences and attitudes of nursing home and home healthcare employees in Switzerland. BMC Infectious Diseases, 2022, 22, 259.	1.3	9
704	Antibody seroprevalence against SARS-CoV-2 within the Canton of Sarajevo, Bosnia and Herzegovinaâ€"One year later. PLoS ONE, 2022, 17, e0265431.	1.1	2
705	Seroprevalence of SARSâ€CoVâ€2 among highâ€density communities and hyperâ€endemicity of COVIDâ€19 in Vietnam. Tropical Medicine and International Health, 2022, 27, 515-521.	1.0	5
706	COVID-Kavach-Based Seropositivity in the General Population of Ahmedabad: Just Before the Start of the Vaccination for the Elderly in India. Cureus, 2022, 14, e22759.	0.2	0
707	Detection, prevention and treatment of COVIDâ€19 and opportunities for nanobiotechnology. View, 2022, 3, .	2.7	8
708	COVID-19 Pandemic and Its Impact on Training Programs of Medical Residency in Romania. Gastroenterology Insights, 2022, 13, 106-116.	0.7	2
709	Seroprevalence of IgG antibodies against SARS-CoV-2 â€“ a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020. Eurosurveillance, 2022, 27, .	3.9	19
710	The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study. Frontiers in Medicine, 2022, 9, 850858.	1.2	3
711	Occupational and community risk of SARS-CoV-2 infection among employees of a long-term care facility: an observational study. Antimicrobial Resistance and Infection Control, 2022, 11, 51.	1.5	8
712	SARS-CoV-2 seroprevalence and determinants of infection in young adults: a population-based seroepidemiological study. Public Health, 2022, 207, 54-61.	1.4	3
713	Seroâ€prevalence of SARSâ€CoVâ€2 in certain cities of Kazakhstan. Health Science Reports, 2022, 5, e562.	0.6	6
714	Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population. Communications Medicine, 2022, 2, .	1.9	10
715	Child transmission of SARS-CoV-2: a systematic review and meta-analysis. BMC Pediatrics, 2022, 22, 172.	0.7	36
716	THE INTERGENERATIONAL MORTALITY TRADEâ€OFF OF COVIDâ€19 LOCKDOWN POLICIES. International Economic Review, 2022, 63, 1427-1468.	0.6	4
717	COVID-positive ankle fracture patients are at increased odds of perioperative surgical complications following open reduction internal fixation surgery. PLoS ONE, 2021, 16, e0262115.	1.1	6
718	Testing Denmark: a Danish Nationwide Surveillance Study of COVID-19. Microbiology Spectrum, 2021, 9, e0133021.	1.2	15
720	Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 10	0.8	7
721	High seroprevalence of SARS-CoV-2 among high-density communities in Saudi Arabia. Infection, 2022, 50, 643-649.	2.3	3

#	Article	IF	Citations
722	Rapid Serological Testing for Managing the COVID-19 Pandemic: A Review. Open Biomarkers Journal, 2021, 11, 99-107.	0.1	0
723	COVID-19: pathogen characteristics, natural and adaptive immune response mechanisms, genetic diversity and distribution. Proceedings of the National Academy of Sciences of Belarus, Medical Series, 2021, 18, 497-512.	0.2	1
724	Association between SARS-CoV-2 Seroprevalence in Nursing Home Staff and Resident COVID-19 Cases and Mortality: A Cross-Sectional Study. Viruses, 2022, 14, 43.	1.5	6
726	Prevalence of SARS-CoV-2 Infection in a Sample of Health Workers in Two Health Departments of the Valencian Community in Spain. International Journal of Environmental Research and Public Health, 2022, 19, 66.	1.2	5
727	Are People Optimistically Biased about the Risk of COVID-19 Infection? Lessons from the First Wave of the Pandemic in Europe. International Journal of Environmental Research and Public Health, 2022, 19, 436.	1.2	31
728	COVID-19 SEROPREVALENCE AMONG ROYAL THAI ARMY PERSONNEL IN BANGKOK METROPOLITAN AREA FROM JULY-SEPTEMBER 2020. , 2020, 4, 67-74.		3
729	Perceptions towards mask use in school children during the SARS-CoV-2 pandemic: descriptive results from the longitudinal Ciao Corona cohort study. , 2022, 152, .		3
730	COVID-19 in Tunisia (North Africa): Seroprevalence of SARS-CoV-2 in the General Population of the Capital City Tunis. Diagnostics, 2022, 12, 971.	1.3	4
735	SARS-CoV-2 seroprevalence in blood donors before and after the first wave in Catalonia (Spain).. Blood Transfusion, 2022, , .	0.3	1
736	German and international studies on SARS-CoV-2 seroprevalence.. , 2020, 5, 2-15.		8
740	Recent Chronology of COVID-19 Pandemic. Frontiers in Public Health, 2022, 10, .	1.3	21
741	Applying mixture model methods to SARS-CoV-2 serosurvey data from Geneva. Epidemics, 2022, 39, 100572.	1.5	2
742	Seroprevalence of SARS-CoV-2 infection and associated factors among Bangladeshi slum and non-slum dwellers in pre-COVID-19 vaccination era: October 2020 to February 2021. PLoS ONE, 2022, 17, e0268093.	1.1	9
743	German federal-state-wide seroprevalence study of 1st SARS-CoV-2 pandemic wave shows importance of long-term antibody test performance. Communications Medicine, 2022, 2, .	1.9	6
744	Assessing the burden of COVID-19 in developing countries: systematic review, meta-analysis and public policy implications. BMJ Global Health, 2022, 7, e008477.	2.0	108
745	Prevalence and determinants of SARS-CoV-2 neutralizing antibodies in Lebanon. Archives of Virology, 2022, 167, 1509-1519.	0.9	5
746	A country-specific model of COVID-19 vaccination coverage needed for herd immunity in adult only or population wide vaccination programme. Epidemics, 2022, 39, 100581.	1.5	2
747	Wastewater-Based Estimation of the Effective Reproductive Number of SARS-CoV-2. Environmental Health Perspectives, 2022, 130, .	2.8	92

#	Article	IF	Citations
748	Prevalence and Dynamics of SARS-CoV-2 Antibodies in the Population of St. Petersburg, Russia. Journal of Epidemiology and Global Health, 0, , .	1.1	0
749	High Level of SARS-CoV-2 Infection in Young Population Is a Predictor for Peak Incidence. Frontiers in Microbiology, 2022, 13, .	1.5	1
750	Seroprevalence of anti-SARS-CoV-2 IgG antibodies: relationship with COVID-19 diagnosis, symptoms, smoking, and method of transmission. IJID Regions, 2022, 4, 10-16.	0.5	3
751	SARS-CoV-2 seroprevalence around the world: an updated systematic review and meta-analysis. European Journal of Medical Research, 2022, 27, .	0.9	10
752	Antibody response three months after SARSâ€CoVâ€2 infection. Journal of Medical Virology, 2022, 94, 4712-4718.	2.5	4
753	Seroprevalence and characteristics of Coronavirus Disease (COVID-19) in workers with non-specific disease symptoms. BMC Infectious Diseases, 2022, 22, .	1.3	4
754	On-the-Job Safety During Enlarging an Intensive Care Unit for the COVID-19 Pandemic: Team-Based Approach with Low Infection Rate of the Staff. , 2022, 50, S42-S49.		0
755	Seroprevalence of SARS-CoV-2 in four states of Nigeria in October 2020: A population-based household survey. PLOS Global Public Health, 2022, 2, e0000363.	0.5	6
757	Determining the SARS-CoV-2 serological immunoassay test performance indices based on the test results frequency distribution. Biochemia Medica, 2022, 32, 217-223.	1.2	1
758	Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies in the Mozambican Population: A Cross-Sectional Serologic Study in 3 Cities, Julyâ€"August 2020. Clinical Infectious Diseases, 2022, 75, S285-S293.	2.9	3
759	COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data. PLoS ONE, 2022, 17, e0266945.	1.1	6
760	Seroprevalence of SARS-CoV-2 Antibodies in Africa: A Systematic Review and Meta-Analysis. International Journal of Environmental Research and Public Health, 2022, 19, 7257.	1.2	13
761	Seroprevalence of SARS-CoV-2 on health professionals via Bayesian estimation: a Brazilian case study before and after vaccines. Acta Tropica, 2022, 233, 106551.	0.9	1
762	SARS-CoV-2 specific IgG antibodies among participants presenting to a voluntary testing facility in Srinagar, Kashmir. Journal of Family Medicine and Primary Care, 2022, 11, 2667.	0.3	0
763	Evaluation of the performance of Panbioâ„¢ COVID-19 antigen rapid diagnostic test for the detection of SARS-CoV-2 in suspected patients in Ethiopia. SAGE Open Medicine, 2022, 10, 205031212211100.	0.7	1
764	SARS-CoV-2 Seroprevalence, Cumulative Infections, and Immunity to Symptomatic Infection â€" A Multistage National Household Survey and Modeling Study, Dominican Republic, Juneâ€"October 2021. SSRN Electronic Journal, 0, , .	0.4	1
765	SARS-CoV-2 Circulation during the First Year of the Pandemic: A Seroprevalence Study from January to December 2020 in Tuscany, Italy. Viruses, 2022, 14, 1441.	1.5	1
766	Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in children and adolescents in Delhi, India, from January to October 2021: a repeated cross-sectional analysis. Osong Public Health and Research Perspectives, 2022, 13, 184-190.	0.7	4

#	Article	IF	Citations
767	SARS-CoV-2 seroprevalence and risk factors among meat packing, produce processing, and farm workers. PLOS Global Public Health, 2022, 2, e0000619.	0.5	3
768	First wave of SARS-CoV-2 in Santiago Chile: seroprevalence, asymptomatic infection and infection fatality rate. Epidemics, 2022, , 100606.	1.5	0
769	Seroprevalence study prior and post vaccination in cancer patients in principality of Andorra (COVONCO study). Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
770	Seroprevalence and dynamics of anti-SARS-CoV-2 antibodies: a longitudinal study based on patients with underlying diseases in Wuhan. Respiratory Research, 2022, 23, .	1.4	3
771	Seroprevalence of anti SARS-CoV-2 IgG antibodies among adults in Jammu district, India: A community-based study. Indian Journal of Medical Research, 2022, 155, 171.	0.4	0
773	EvaluaciÃ³n de la seroconversiÃ³n de anticuerpos contra SARS-COV-2. Magna Scientia UCEVA, 2022, 2, 48-55.	0.1	0
774	Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022. Eurosurveillance, 2022, 27, .	3.9	11
775	Ancestral SARS-CoV-2, but not Omicron, replicates less efficiently in primary pediatric nasal epithelial cells. PLoS Biology, 2022, 20, e3001728.	2.6	15
776	Longitudinal change in SARS-CoV-2 seroprevalence in 3-to 16-year-old children: The Augsburg Plus study. PLoS ONE, 2022, 17, e0272874.	1.1	6
777	SARS-CoV-2 Seroprevalence at an Urban Hospital in Haiti. Cureus, 2022, , .	0.2	3
778	Prevalence assessment adjusted for laboratory test performance using an example of the COVID-19 serological tests. Ekologiya Cheloveka (Human Ecology), 2022, 29, 301-309.	0.2	2
779	A pre-vaccine exploratory survey of SARS-CoV-2 humoral immunity among Egyptian general population. Tropical Medicine and Health, 2022, 50, .	1.0	5
780	SARS-CoV-2 seroprevalence in hospital healthcare workers in Western Switzerland at the end of the second pandemic wave. Journal of Medical Microbiology, 2022, 71, .	0.7	1
781	SARS-CoV-2 infections in infants in Haiti 2020â€“2021; evidence from a seroepidemiological cohort. PLoS ONE, 2022, 17, e0273482.	1.1	3
783	The SARS-CoV-2 Antibodies, Their Diagnostic Utility, and Their Potential for Vaccine Development. Vaccines, 2022, 10, 1346.	2.1	4
784	Impacts of timing, length, and intensity of behavioral interventions to COVID-19 dynamics: North Carolina county-level examples. Infectious Disease Modelling, 2022, 7, 535-544.	1.2	0
785	Current clinical testing approach of COVID. , 2022, , 231-274.		0
786	Incidence of COVID-19 among individuals vaccinated with ChAdOx1 nCoV-19 vaccine (recombinant) against SARS-CoV-2 at a tertiary health care centre in Telangana. Indian Journal of Medical Research, 2022, 155, 211.	0.4	0

#	Article	IF	Citations
787	Clinical Manifestations, Epidemiologic Characteristics, and Disease Burden of the Coronavirus Disease-19 in Children Ages 5-11 Years Old. Pediatric Infection and Vaccine, 2022, 29, 61.	0.1	3
789	Structural factors associated with SARS-CoV-2 infection risk in an urban slum setting in Salvador, Brazil: A cross-sectional survey. PLoS Medicine, 2022, 19, e1004093.	3.9	12
790	SARS-CoV-2 IgG Antibody Seroprevalence in Children from the Amritsar District of Punjab. Korean Journal of Clinical Laboratory Science, 2022, 54, 173-178.	0.1	0
791	Knowledge of SARS-CoV-2 Epitopes and Population HLA Types Is Important in the Design of COVID-19 Vaccines. Vaccines, 2022, 10, 1606.	2.1	4
792	Long-Term Antibody Response to SARS-CoV-2 in Children. Journal of Clinical Immunology, 2023, 43, 46-56.	2.0	8
793	Seroprevalence of SARS-CoV-2 in Health-care Personnel from the State of Guanajuato, Mexico: A Cross-Sectional Study. Biomedical and Pharmacology Journal, 2022, 15, 1427-1436.	0.2	0
795	Optimizing prevalence estimates for a novel pathogen by reducing uncertainty in test characteristics. Epidemics, 2022, 41, 100634.	1.5	1
797	The SARS-CoV-2 Infection Among Students in the University of Porto: A Cross-Sectional Study. International Journal of Public Health, 0, 67, .	1.0	4
798	High Prevalence of Undocumented SARS-CoV-2 Infections in the Pediatric Population of the Tyrolean District of Schwaz. Viruses, 2022, 14, 2294.	1.5	2
799	SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria. JAMA Network Open, 2022, 5, e2236053.	2.8	9
800	SARS-CoV-2 seroprevalence study after the first wave among persons living and working in an overcrowded Swiss prison. International Journal of Prisoner Health, 2022, ahead-of-print, .	0.5	0
801	Quantitatively evaluate the impact of domestic aviation control measures on the spread of COVID-19 in China. Scientific Reports, 2022, 12, .	1.6	0
802	Comparison of two antibody screening systems for SARS-CoV-2 antibody detection in recovered and vaccinated subjects - test performance and possible indicators for immunity. Journal of Clinical Virology, 2022, 157, 105322.	1.6	3
803	Distribution characteristics of SARS-CoV-2 IgM/IgG in false-positive results detected by chemiluminescent immunoassay. Open Life Sciences, 2022, 17, 1487-1496.	0.6	0
804	Seroprevalence of anti-SARS-CoV-2 antibodies among children and their parents in Greece. European Journal of Pediatrics, 2023, 182, 439-449.	1.3	2
805	SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection â€“ A multistage national household survey and modelling study, Dominican Republic, Juneâ€“October 2021. The Lancet Regional Health Americas, 2022, 16, 100390.	1.5	2
806	Seroprevalence SARS-CoV-2 among the academic population of Universitas Gadjah Mada Yogyakarta. Bali Medical Journal, 2022, 11, 382-386.	0.1	0
807	A population-based serological study of post-COVID syndrome prevalence and risk factors in children and adolescents. Nature Communications, 2022, 13, .	5.8	8

#	Article	IF	Citations
808	Seroprevalence of SARS-CoV-2 antibodies among Forcibly Displaced Myanmar Nationals in Coxâ€™s Bazar, Bangladesh 2020: a population-based cross-sectional study. BMJ Open, 2022, 12, e066653.	0.8	0
809	Prevalence of bacterial co infections among Covid 19 patients in wasit province. International Journal of Health Sciences, 0, , 48971-48984.	0.0	0
810	High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Children in Vietnam: An Observational, Hospital-Based Study. Pathogens, 2022, 11, 1442.	1.2	0
812	Population-based sero-epidemiological investigation of the dynamics of SARS-CoV-2 infections in the Greater Accra Region of Ghana. Scientific Reports, 2022, 12, .	1.6	2
814	Prevalence of Anti-SARS-CoV-2 Antibodies in HIV-Positive Patients in Wroclaw, Polandâ€"Unexpected Difference between First and Second Wave. Covid, 2022, 2, 1748-1757.	0.7	0
815	The prevalence of SARS-CoV-2 antibodies within the community of a private tertiary university in the Philippines: A serial cross sectional study. PLoS ONE, 2022, 17, e0268145.	1.1	2
816	Community-Based Seroprevelance of SARS-CoV-2 in Saudi Arabia. Cureus, 2022, , .	0.2	0
817	The Impact of Coronavirus Infection on Health-Related Quality of Life in Amateur CrossFit Athletes. International Journal of Environmental Research and Public Health, 2022, 19, 16409.	1.2	2
818	Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study. Lancet Regional Health - Europe, The, 2023, 24, 100547.	3.0	18
819	Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada. Cmaj, 2022, 194, E1599-E1609.	0.9	25
820	Associations between Depression and Self-Reported COVID-19 Symptoms among Adults: Results from Two Population-Based Seroprevalence Studies in Switzerland. International Journal of Environmental Research and Public Health, 2022, 19, 16696.	1.2	2
822	Disparities in SARS-CoV-2 Infection by Race, Ethnicity, Language, and Social Vulnerability: Evidence from a Citywide Seroprevalence Study in Massachusetts, USA. Journal of Racial and Ethnic Health Disparities, 2024, 11, 110-120.	1.8	3
823	Main modulators of COVID-19 epidemic in sub-Saharan Africa. Heliyon, 2023, 9, e12727.	1.4	3
824	High SARS-CoV-2 antibody prevalence after the third epidemic wave (May â€“ October 2021) in Matadi, Democratic Republic of the Congo. Open Forum Infectious Diseases, 0, , .	0.4	1
825	Prevalence and predictors of psychological distress before, during, and after a COVID-19 pandemic wave in Switzerland, 2021. Journal of Psychiatric Research, 2023, 158, 192-201.	1.5	3
826	COVID-19 in Older Adults. , 2023, , 1-19.		0
827	Reactogenicity within the first week after Sinopharm, Sputnik V, AZD1222, and COVIran Barekat vaccines: findings from the Iranian active vaccine surveillance system. BMC Infectious Diseases, 2023, 23, .	1.3	1
828	Persistent COVID-19 symptoms in community-living older adults from the Canadian Longitudinal Study on Aging (CLSA). Communications Medicine, 2023, 3, .	1.9	4

#	Article	IF	Citations
829	Inpatient post-COVID-19 rehabilitation program featuring virtual realityâ€"Preliminary results of randomized controlled trial. Frontiers in Public Health, 0, 11, .	1.3	6
831	National and regional prevalence of SARS-CoV-2 antibodies in primary and secondary school children in England: the School Infection Survey, a national open cohort study, November 2021SARS-CoV-2 antibody prevalence in school children. Journal of Infection, 2023, 86, 361-368.	1.7	2
834	Editorial: Current research on serological analyses of infectious diseases. Frontiers in Medicine, 0, 10, .	1.2	2
835	A free boundary problem-in time-for the spread of Covid-19. Journal of Mathematical Biology, 2023, 86, .	0.8	2
836	Case Report of Serum Sickness-like Reaction following the First Dose of the Chimpanzee Adenovirus-Vectored AstraZeneca COVID-19 Vaccine, ChAdOx1. Vaccines, 2023, 11, 467.	2.1	1
837	Trajectories of Seroprevalence and Neutralizing Activity of Antibodies against SARS-CoV-2 in Southern Switzerland between July 2020 and July 2021: An Ongoing, Prospective Population-Based Cohort Study. International Journal of Environmental Research and Public Health, 2023, 20, 3703.	1.2	2
838	Cumulative incidence of SARS-CoV-2 infection within the homeless population: insights from a city-wide longitudinal study. BMJ Open, 2023, 13, e065734.	0.8	4
839	Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: a population-based study. Infection, 2023, 51, 1453-1465.	2.3	0
840	Functional outcomes in post Covid-19 patients with persistent dyspnea: multidisciplinary approach. International Journal of Cardiovascular Imaging, 0, , .	0.7	0
842	Clinical sensitivity and specificity of a high-throughput microfluidic nano-immunoassay combined with capillary blood microsampling for the identification of anti-SARS-CoV-2 Spike IgG serostatus. PLoS ONE, 2023, 18, e0283149.	1.1	1
843	Parental willingness to have children vaccinated against COVID-19 in Geneva, Switzerland: a cross-sectional population-based study. Swiss Medical Weekly, 2023, 153, 40049.	0.8	1
844	Trends in management and outcomes of COVID patients admitted to a Swiss tertiary care hospital. Scientific Reports, 2023, 13, .	1.6	1
845	Seroprevalence and SARS-CoV-2 invasion in general populations: A scoping review over the first year of the pandemic. PLoS ONE, 2023, 18, e0269104.	1.1	3
846	Seroprevalence of SARS-CoV-2 specific Immunoglobin G antibodies in rural population of Western Maharashtra, India. Journal of Global Health, 0, 13, .	1.2	0
847	A Mixture Model for Estimating SARS-CoV-2 Seroprevalence in Chennai, India. American Journal of Epidemiology, 2023, 192, 1552-1561.	1.6	1
862	The Impact of COVID-19 on Diabetic Foot Ulcers. Contemporary Endocrinology, 2023, , 79-91.	0.3	0
865	A critical appraisal of the toxicological aspects of COVID-19 and its vaccines. , 2024, , 1-11.		0
917	COVID-19 in Older Adults. , 2024, , 761-779.		0

#	Article	IF	Citations